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ABSTRACT 
 
Hot-melt extrusion (HME) is a promising technology for the production of new 
Chemical entities in the developmental pipeline and for improving products already on the 
market. The first objective of this research work was to describe a continuous process for the 
production of solid lipid nanoparticles (SLN) as drug-carrier systems via hot-melt extrusion 
(HME) using Quality by Design (QbD) principles. Fenofibrate SLN were prepared by combining 
two processes: HME technology for melt-emulsification and high-pressure homogenization 
(HPH) for size reduction. Varying the process parameters enabled the production of SLN below 
200 nm. At the end of a 5-h in-vitro dissolution study, a SLN formulation released 92– 93% of 
drug, whereas drug release was approximately 65% and 45% for the marketed micronized 
formulation and crude drug, respectively. The second objective of this research work was to 
develop pH-independent/dependent sustained release (SR) tablets of ondansetron HCl dihydrate 
(OND). The in-vitro release study demonstrated sustained release for 24 h with 90% of drug 
release in formulations using stearic acid in combination with ethyl cellulose, whereas 100% 
drug release in 8 h for stearic acid-hydroxypropylcellulose matrices. The third objective of this 
research work was apply a QbD approach based on design of experiments as a risk-based 
proactive approach to achieve predictable critical quality attributes (CQAs) to develop a dry-
granulation process for controlled release formulation of OND SR tablets by twin-screw 
extruder. The effect of screw speed, feed rate and amount of fumaric acid on the particle size and 
flow properties of the granules and time required for complete and controlled release of the drug 
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from the dosage was optimized by 23 factorial design. Based on the design of experiment (DOE) 
results, a formulation comprising of 2.5 % (w/w) fumaric acid extruded at high screw speed (100 
rpm) and low feed rate (1%) was found to fulfill requisites of an optimum formulation. The 
fourth objective was to understand the dehydration behavior of OND during HME process. 
Hydrates of active pharmaceutical ingredients may undergo dehydration during the 
manufacturing process and/or storage. This can affect the physiochemical properties of the 
formulation including solubility, dissolution rate, bioavailability and stability. 
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CHAPTER I 
HOT-MELT EXTRUSION TECHNOLOGY 
 
1.1 Introduction 
Hot-melt extrusion (HME) processing was established in the early 1930s, and during that 
time, it rapidly became the most widely applied processing technology in the plastic, rubber, and 
food industries. The application of HME expanded to the pharmaceutical industry at the 
beginning of the 1970s and was used in formulation and product development as well as 
manufacturing. The first application of HME as a manufacturing tool in the pharmaceutical 
industry was investigated by El-Egakey et al. (1971) using poly (vinyl acetate-co-methacrylic 
acid) and epoxy resin containing a secondary amine as a polymeric carrier [1]. HME is a 
continuous pharmaceutical process that involves pumping polymeric materials with a rotating 
screw at temperatures above their glass transition temperature (Tg) and sometimes above the 
melting temperature (Tm) to achieve molecular level mixing of the active compounds and 
thermoplastic binders, polymers, or both. This molecular mixing converts the components into 
an amorphous product with a uniform shape and density, thereby increasing the dissolution 
profile of the poorly water-soluble drug. Additionally, HME has been utilized for the delivery of 
water soluble drugs with several applications such as taste masking [2]. This exciting yet 
challenging technology may offer several advantages over conventional pharmaceutical 
manufacturing processes such as shorter and more efficient time to achieve the final product 
environmental advantages due to the elimination of solvent use, and increased efficiency of drug 
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delivery to the patient. As a result, HME has emerged as an alternative “platform technology” to 
other traditional techniques for manufacturing pharmaceutical dosage forms such as tablets, 
capsules, films, and implants for drug delivery via oral, transdermal, and transmucosal routes. 
The introduction of HME to pharmaceutical formulation development has made sophisticated 
equipment such as the extruder, customized downstream auxiliary equipment, and monitoring 
tools available for application in the evaluating the performance and product quality. This 
enhanced availability has supported the growth of this innovative technique in pharmaceutical 
manufacturing processes utilizing both single and twin-screw extruders.  
To date, several research articles have been published describing the use of HME as the 
novel technique of choice in dealing with the day-to-day formulation challenges of new active 
pharmaceutical ingredients (APIs). Moreover, numerous aspects of the HME technology have 
been extensively cited in the literature. Additionally, the number of patents based on HME 
techniques has risen steadily worldwide in recent decades [3-11].  
Regulatory bodies continue to encourage the investment in the use of quality by design 
(QbD) and process analytical technology (PAT), which are already essential tools in the HME 
process, to enhance product and process understanding. As a continuous process, HME fits 
perfectly within this framework. PAT tools including Raman and near infrared (NIR) 
spectroscopy play an important role in real–time quality evaluation and understanding of the 
extrusion process in the production pharmaceutical dosage forms. 
1.2. Hot-Melt Extrusion: Equipment and Process 
1.2.1. Equipment 
Pharmaceutical-class extruders have evolved and adapted to mix APIs with carriers, 
plasticizers, or with other processing aids to develop various solid dosage forms. The major 
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difference between the pharmaceutical-class extruder and a “plastic extruder” are the contact 
parts, which are specifically configured to meet the current regulatory norms of manufacturing 
dosage forms [4]. The HME process is implemented using the equipment that mainly consists of 
an extruder, ancillary equipment for the extruder, downstream processing equipment, and other 
controlling tools used for performance and product quality evaluation. The extruder generally 
consists of a feeding hopper that is the opening through which material enters the barrel, a 
conveying section that is comprised of barrels and single or twin screws, the die for shaping the 
extrudates and a screw-driving unit. The ancillary equipment for the extruder consists of a 
heating/cooling device for the barrels, a conveyer belt to cool down the product and a solvent 
delivery pump for cooling, cutting, and/or collecting the finished product [12]. The controlling 
devices on the equipment include temperature gauges, a screw-speed controller, an extrusion 
torque monitor, and pressure gauges. 
Different types of screw extruders are available such as single or multi-screw extruders. 
Multiscrew extruders can involve either two screws (twin screw design) or generally up to four. 
Single screw extruders (SSE) are still utilized within the plastics field; however, their use in 
pharmaceuticals is limited. SSE consists of one rotating screw inside a stationary cylindrical 
barrel subdivided into three distinct zones: feeding zone, compressing zone, and metering zone. 
The barrel is generally manufactured in sections, which are either bolted or clamped with each 
other. The three primary functions of SSE are conveying, melting, and pumping polymers into a 
desired shape. The shape of the extruded product depends on the type of die connected to the end 
of the barrel [3]. Mechanical simplicity and a low cost of investment and minimal maintenance 
make SSE a good choice for the manufacturing of plastic extruded products. However, it has 
some limitations, such as poor mixing capability, and, therefore, it is not the preferred option for 
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the manufacturing of most of the pharmaceutical formulations where high kneading and 
dispersing capacities are required. To overcome the stated limitations of SSE, multiscrew 
extruders were developed. The first twin-screw extruder (TSE) was developed in the late 1930s 
in Italy. The TSE has two agitator assemblies mounted on parallel shafts. Different types of TSE 
are available with each type having distinct operating principles and applications in processing. 
The two main types of TSE are either co-rotating (rotate in the same direction) or counter-
rotating (the opposite direction). These two types of TSE can further be classified as either fully 
intermeshing or non-intermeshing [13, 14]. Schematic presentation of a TSE setup is provided in 
Figure 11.1. 
 
Fig 1.1: Schematic diagram of twin-screw extruder 
The difference between SSE and multiscrew extruders is their mode of operation. In an 
SSE, friction between the material and the rotating screw allows the material to rotate with the 
screw, and the friction between the rotating material and the barrel pushes the material forward, 
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which results in the generation of heat. Therefore, for achieving high throughput in SSE by 
increasing screw speed results in the increase in frictional heat and therefore higher temperatures. 
Whereas, intermeshing screws of TSEs pushes the material forward with the relative motion of 
the flight of one screw inside the channel of the other. In TSEs, heat is therefore controlled 
independently from an outside source and is not influenced by screw speed. This difference in 
the operation becomes important when processing a thermos labile drug. 
When compared with SSE, intermeshing corotating TSEs generally provides better 
mixing to produce a homogeneous solid containing finely distributed and dispersed active 
compounds, better melt temperature control therefore less tendency to overheat, little 
dependence on the materials friction coefficients, and short transit time due to relatively fast 
melting [13, 14]. 
1.2.2. Process 
Although HME is considered as a unit operation, for a theoretical understanding, the 
process can be categorized into the following sub processes:[3, 4, 12-14] 
1. Material feeding of the extruder with assistance of a hopper. 
2. Conveying of mass. 
3. Flow through the die. 
4. Finally, extrudates from the die and subsequent downstream processing. 
1. Material feeding: Active compounds, carriers, plasticizers, or other processing excipients can 
be used as a preblend or can be introduced as an individual feed stream with the aid of a 
hopper(s) through feeding zone of the extruder by using either gravimetric (loss-in-weight) or 
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volumetric feeders. The preblend must have good flow. Feed rate, feed type, and oscillation in 
feeding rate affects the degree of fill, which influences the homogeneity, thermal, and 
mechanical energy input into the formulation. 
2. Conveying of mass: The material enters the feeder onto the rotating screws and is transported 
toward the die in the conveying section. This section includes several operations, such as 
melting, mixing, grinding, reduction in particle size, venting, and kneading. Therefore, the 
conveying process is mainly dependent upon screw speed and filling level, melting point of the 
individual components, particle size of the components, residence time, and screw configuration 
[15]. Modified screw designs are used when high shear is required to prepare an extrudate. 
Different types of screw elements to achieve desired results are shown in Figure 1.2. 
3. Flow through the die: At the end of barrel, a die is attached to the extruder in order to extrude 
the material. After the conveying section, the next step within the extrusion process is to pump 
the molten mass into the die. Different shapes of a die are available and are used depending on 
the desired end product shape. 
4. Extrusion from the die and following downstream processing: Just before the die, high 
pressure is generally incurred, which allows nearly 100 % screw fill level and ensures a constant 
melt flow through the die to provide an even shaping. Once the molten mass exit from the die, 
downstream processing plays a role into finishing, shaping, and analyzing the extruded product. 
The finishing process entails different downstream ancillary components are involved, such as 
conveyor belts that transfer the extruded product from the die to the end of the processing line. 
The molten extrudates are often cooled by chill rolls and then either milled into powder or cut 
into rods by a strand-cutter. Sometimes pelletizers are also used to cut the extrudates into smaller 
units. 
 6 
 
                                                                                                                                                                         
 
                    Kneader 
                                               
                                                     
 Conveyer 
           
Fig1.2: Modular screws design 
1.3. Advantages and Disadvantages of Hot-Melt Extrusion 
HME offers several distinct advantages over conventional pharmaceutical formulation 
techniques [2-4, 11-14] 
1. HME is a continuous and efficient process, which thus enables high throughput, online 
monitoring, minimal and controlled processing, and manageable process variables. 
2. Solvent free techniques also reduce the number of processing steps and eliminate the time 
consuming drying step. Also, there is no need to handle potentially dangerous solvents, resulting 
in the absence of residual solvents in the final formulation. 
3. HME increases the solubility and potential bioavailability of poorly water-soluble and 
insoluble compounds, mainly by molecular dispersion of the drug within the final dosage form. 
4. This processing technique may not require major downstream processing such as compression 
(tablets, etc.). 
5. Uniform dispersion of fine particles resulting from the intense mixing and agitation imposed 
by the rotating screw, which cause de-aggregation of suspended particles in the molten polymer, 
is another attribute of this technology. 
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6. Properly processed, one can achieve good stability at various pHs and moisture levels. 
7. Wide array of pharmaceutical dosage forms such as pellets, granules, sustained/controlled 
release, oral fast dissolving system, targeted release such as transdermal, transmucosal, and 
transungual delivery system and implants. HME has also recently been used for taste-masking 
and drug-abuse deterrent products. 
8. Fortunately, the equipment has a wide range of screw geometries available for processing. 
9. HME technology is useful for low compressibility index APIs. Poorly compactable material 
can be easily compressed into tablets by this technique. 
10. Compared to other techniques, hot-melt extruded solid solutions are thermodynamically 
stable if proper planning of the process is utilized. 
Even though HME offers several advantages, like any pharmaceutical processing technique, it 
entails a few disadvantages, which includes the following. However, some of these can be 
managed and minimized: 
1. HME may require high processing temperatures, which tend to limit its applicability in 
processing of thermolabile compounds. Thus, it is not suitable for relatively high heat sensitive 
molecules such as proteins and microbial species. 
2. There are a finite number of heat-stable polymers. 
3. The process requires high energy input. 
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CHAPTER II 
 
CONTINUOUS PRODUCTION OF FENOFIBRATE SOLID LIPID NANOPARTICLES 
BY HOT-MELT EXTRUSION TECHNOLOGY: A SYSTEMATIC STUDY BASED ON A 
QUALITY BY DESIGN APPROACH 
 
2.1. Abstract 
This contribution describes a continuous process for the production of solid lipid 
nanoparticles (SLN) as drug-carrier systems via hot-melt extrusion (HME). Presently, HME 
technology has not been used for the manufacturing of SLN. Generally, SLN are prepared as a 
batch process, which is time consuming and may result in variability of end-product quality 
attributes. In this study, using Quality by Design (QbD) principles, we were able to achieve 
continuous production of SLN by combining two processes: HME technology for melt-
emulsification and high-pressure homogenization (HPH) for size reduction. Fenofibrate (FBT), a 
poorly water-soluble model drug, was incorporated into SLN using HME-HPH methods. The 
developed novel platform demonstrated better process control and size reduction compared to the 
conventional process of hot homogenization (batch process). Varying the process parameters 
enabled the production of SLN below 200 nm. The dissolution profile of the FBT SLN prepared 
by the novel HME-HPH method was faster than that of the crude FBT and a micronized 
marketed FBT formulation. At the end of a 5-h in vitro dissolution study, a SLN formulation 
 9 
 
released 92–93% of drug, whereas drug release was approximately 65 and 45% for the marketed 
micronized formulation and crude drug, respectively. Also, pharmacokinetic study results 
demonstrated a statistical increase in Cmax, Tmax, and AUC0–24 h in the rate of drug 
absorption from SLN formulations as compared to the crude drug and marketed micronized 
formulation. In summary, the present study demonstrated the potential use of hot-melt extrusion 
technology for continuous and large-scale production of SLN. 
2.2. Introduction: 
Quality by design (QbD) is a holistic, systematic, risk-based proactive approach aimed at 
final product quality. This approach begins with predefined objectives to ensure predictable 
product quality. The main purpose of QbD is to identify and control critical parameters which 
affect product quality [16-18]. QbD has been promoted by the United States Food and Drug 
Administration (US FDA) as a way to enhance pharmaceutical development through design 
efforts from product conceptualization to commercialization [19]. Formulation of drugs, which 
are poorly water soluble, is the most challenging problem with respect to their biopharmaceutic 
quality, because slow and erratic dissolution prevents these compounds from being rapidly and 
completely absorbed from the gastrointestinal tract [20]. Several nanosized formulations were 
developed recently to overcome these problems [21]. In these nanosized formulations, solid lipid 
nanoparticles (SLN) are one of the potential drug delivery systems and have been reported for 
controlled drug delivery, bioavailability enhancement by modification of dissolution rate and/or 
by improving tissue distribution and, targeting of drugs by using various application routes. SLN 
are mainly formulated by non-solvent or solvent-based techniques. The solvent-based technique 
utilizes organic solvents to dissolve the solid lipid; the solvent is then evaporated from the 
emulsion to obtain SLN. In the non-solvent technique, the solid lipid is liquefied over its melting 
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point and is subsequently converted to nanoemulsions through common techniques such as high-
pressure homogenization, in which cooling further results in SLN [5]. 
For more than two decades, fibrates played an important role in the treatment of 
hyperlipidemia. Fenofibrate (FBT) is one of the most commonly used fibrate worldwide. FBT is 
a pro-drug of fenofibric acid, approved to treat hypertriglyceridemia because it reduces low-
density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) while increasing the level 
of high-density lipoprotein (HDL) [22, 23]. It belongs to BCS II, which means that it is lipophilic 
with a logP value of 5.6 and practically insoluble in water [22, 24, 25]. The major drawback of 
FBT is its low bioavailability when taken under fasting conditions. Thus, there is a need to 
develop a new formulation/process in order to increase the FBT dissolution rate and improve its 
oral bioavailability.  
High pressure homogenization (HPH) has emerged as a reliable and powerful technique 
for the preparation of SLN [25]. HPH (hot and cold homogenization) have been explored for the 
feasibility in scaling-up. However, these methods for SLN preparation needs a preparatory step 
that involves the drug incorporation into the bulk lipid which in-turn involves multistep 
processes such as melting of lipid, dispersion or dissolution of drugs in melted lipid, preparation 
of aqueous dispersions and finally size reduction, which makes this as a batch process. The 
pharmaceutical industry prefers a continuous process over a batch process as the continuous 
process is economical, it decreases the cost of production by less need of space, labor and 
resources as well as provides high efficacy and more desired product quality. On the other hand 
batch processes require careful and complex procedures and controls to prevent variations in the 
final product. During the manufacturing of SLN, emulsion preparation is often an essential step. 
Emulsion preparation is a batch process, while size reduction by high pressure homogenization is 
 11 
 
a continuous process. Thus, the development of a continuous emulsion preparation process is an 
essential aspect to allow a fully continuous SLN production line. Therefore, new approaches are 
essential to both increase the quality of the product and to reduce the production time.  
Hot-melt extrusion (HME) is an innovative technology for the production of a variety of 
dosage forms. HME technology may offer several advantages over conventional pharmaceutical 
manufacturing processes. Shorter and more efficient times to the final product, environmental 
advantages due to elimination of solvents in processing and increased efficiency of drug delivery 
to the patient make HME an exciting challenge for the pharma scientists and executives. Thus, 
HME has emerged as an alternative “platform technology” to other traditional techniques for 
pharmaceutical dosage forms, such as tablets, capsules, films and implants for drug delivery via 
oral, transdermal and transmucosal routes. HME technology is a potential continuous process of 
pumping raw materials at high temperatures and pressures resulting in a product of uniform 
shape and density [2, 3, 12]. To date several research articles have been published describing the 
use of HME as a novel technique of choice to deal with day-to-day formulation challenges of 
new active pharmaceutical ingredients (API). To the best of our knowledge, HME has not been 
reported in the literature for the manufacturing of SLN and this study utilizes HME technology 
for the manufacturing of drug-loaded SLN. The purpose of this current work was to develop a 
continuous process for SLN production using hot-melt extrusion for preparing a pre-emulsion 
and high pressure homogenization for further size reduction using the poorly water-soluble drug 
FBT as a model drug. In the present work, we will propose an improved method i.e HME-HPH 
method for the continuous production of FBT SLN, using Quality by Design (QbD) principles 
and a design of experiment (DOE) approach. We have used a Plackett-Burmen design in our 
present study to prepare FBT SLN. 
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2.3 Materials and Methods: 
2.3.1. Materials: 
Fenofibrate was purchased from Ria International (East Hanover, NJ, USA). Dynasan® 
114 (trimyristin) and Imwitor® 900 K (Glyceryl stearate) were offered from Sasol Germany 
GmbH (Witten, Germany). Stearic acid, Compritol® 888 ATO (Glyceryl Dibehenate EP) and 
Precirol® ATO 5 (Glycerol Distearate (Type I) EP) was a kind gift from Gattafosse (USA). 
Cremophore EL and Tween 80 were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Lofibra® (200 mg micronized FBT capsule) was a commercial product produced by Global 
Pharmaceuticals (Chalfont, PA, USA). HPLC grade Acetonitrile was obtained from Fisher 
Scientific (USA). D.I water was used throughout the study. All other chemicals were of 
analytical grade. 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.1: Schematic representation of Continuous Preparation of SLNs using Hot Melt 
Extrusion connected to High Pressure Homogenizer 
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2.3.2 Experimental set up: 
A schematic illustration of SLN formation by HME-HPH system is shown in Fig 2.1. Briefly, it 
consists of two parts, a hot melt extruder and high pressure homogenizer. Extruder is typically 
consisting of a motor, which act as a drive unit, feeding hopper, an extrusion barrel, a rotating 
screw and an extrusion die. An electronic control unit is connected to the extruder which controls 
the screw speed, temperature, pressure, and feed rate. Generally one or two rotating screws are 
used inside a stationary cylindrical barrel. Here we are using two rotating screws inside the 
stationary cylindrical barrel. For this study we are using two different types of screw 
configuration i.e standard configuration and modified configuration (Fig. 2.2). Extruder barrel 
consist of 8 zones. First zone is used for the drug-lipid physical mixture feeding and either zone 
3 or zone 4 was used for the addition of surfactant aqueous solution. The first part that is 
extruder is connected to the second part high pressure homogenizer via connector which is 
insulated to prevent the loss of heat.  
 
Fig 2.2: Screw Configuration and Mixing zones used in the preparation of SLNs by HME 
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2.3.3. Preparation of Fenofibrate SLN: 
2.3.3.1 Solubility Studies:  
Solubility studies were performed to identify suitable lipids for the development of the FBT 
SLN. The lipid used in the system should have high solubilization capacity for the drug, ensuring 
the solubilization of the drug in the resultant dispersion. The screening of lipids was performed 
by evaluating the solubility of FBT (10-25 % w/w with respect to lipid mass) in different lipids 
such as Stearic acid, Compritol® 888 ATO, Precirol® ATO 5, Dynasan 114 and Imwitor® 900 K. 
Measured 10 – 25 mg of FBT was added into each vial containing 100 mg of selected excipient. 
Then, the mixture was heated at 90 °C in a water bath to facilitate the solubilization and the melt 
of drug and lipid were physically observed to confirm the presence or absence of insoluble drug 
crystals. 
2.3.3.2 Preliminary study:  
Preliminary study was conducted to identify process variables to be used for the preparation of 
FBT SLN. In the preliminary study formulation variables for SLN such as drug concentration, 
lipid concentration, surfactant concentration, different lipid and different surfactant were 
optimized to obtain SLN with particle size below 200 nm with maximum entrapment efficiency. 
Further, process variables such as screw configuration, barrel temperature, zone of liquid 
addition and screw speed were optimized. Ishikawa diagram (also known as fish-bone diagrams, 
or cause-and-effect diagrams) were constructed to identify the potential risks and corresponding 
causes was created to identify quality attributes for the better performance of developed FBT 
SLN by HME-HPH technique (Fig. 2.3). Particle size, polydispersibility index, zeta potential and 
entrapment efficiency were found to be critical quality attributes of the FBT SLN. Factors 
responsible for these quality attributes were identified as critical process parameters. Plackett-
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Burmen screening experimental design was commonly used to identify these CPP that influence 
product critical quality attributes. 
 
Fig 2.3: Modified Ishikawa Diagram 
 
2.3.3.3 Formulation of FBT SLN:  
SLN were prepared by mixing a lipid and aqueous phase containing surfactant inside the 
extruder barrel at temperatures 10-15 °C above the melting point of the lipid which results in the 
formation of an emulsion. The selected lipids (Compritol® 888 ATO/Precirol® ATO 5) and FBT 
geometric mixture was fed into the co-rotating twin-screw extruder (11 mm Process 11, Thermo-
Fisher Scientific Karlsruhe, Germany) using a volumetric feeder. Different concentrations of a 
surfactant Cremophore EL (Sigma Aldrich, USA) /Pluronic® F 68(BASF,USA) aqueous 
solution, equivalent to the extrusion temperature, was injected into the extruder barrel either zone 
3 or zone 4 through an injection port using a peristaltic pump. The barrel temperature for zone 2 
was either 150 °C or 120 °C; Zone 3 and the rest of the zones including the die temperature were 
kept at 90 °C. Screw speed for all of the formulations was either 160 rpm or 240 rpm. The hot 
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pre-emulsion resulted from hot-melt extrusion was passed through an insulated tube connecting 
to the HME die and sample holder of the high pressure homogenizer (Avestin Emulsiflex C5, 
Canada) for size reduction. The HPH was performed at 85 °C and 1000 bar pressure with two 
repeated cycles to reduce the particle size of pre-emulsion resulting from melt extrusion. The 
HPH parameters were constant for all of the batches. Further, the size-reduced emulsion was 
cooled at room temperature to obtain SLN. The melt extrusion was performed by varying the 
formulation parameters such as drug concentration (DC), surfactant concentration (SC), lipid 
concentration (LC), surfactant (ST), lipid (LT) and by varying process parameters such as screw 
speed (SS), barrel temperature (BT) and zone of liquid addition (ZA). 
2.3.3.4. Design of Experiment: 
A set of Plackett-Burmen (PB) screening design was adopted to study the effect of critical 
process parameters on FBT SLN performance and characteristics. PB design is one of the most 
commonly used designs of experiment. They are the resolution three designs so they can be used 
when only main effects are of interest to be investigated. PB designs involve a large number of 
variables and relatively fewer runs. A total of 12 experimental trials with PB design were 
constructed using design expert stat-ease software version 9. Multilinear regression analysis and 
one way ANOVA were performed to test the significance of the model and the factor 
coefficients. The experimental runs (formulations) were prepared in triplicate. The dependent 
variables were average particle size (Y1), polydispersibility index (Y2), zeta potential (Y3), 
entrapment efficiency (Y4). The linear equation of the model is as follows: 
Y = b0 + b1X1 + b2X2 + b3X3 + b4X4 + b5X5 + ·· ·+ bnXn…………….eq. 1 
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Where Y is the response, b0 is the constant and b1, b2.  . .bn is the coefficient of factor X1, X2.  . 
.Xn (representing the effect of each factor ordered within −1, +1). 
 
2.3.3.5. HPLC analysis of fenofibrate in-vitro: 
A Waters HPLC-UV system (Waters Corp, Milford, MA, USA) and UV detector set at 
wavelength of 286 nm. The separation of fenofibrate was performed on a Symmetry Shield RP 
18 (5 μm) 4.6 × 250 mm column at 35 °C, eluted with acetonitrile and phosphoric acid in water 
(pH = 2.8) at a ratio of 85:15 (v/v). The mobile phase flow rate was maintained at 1.0 mL/min. 
Fenofibrate retention time was 7 min under these conditions. Injection volume was 20 μL. All of 
the HPLC data was analyzed using Empower V. software (Milford, MA, USA). The calibration 
curve was linear with a correlation coefficient of 0.9998 over the range of 0.5-50 µg/ml. The 
within-day and between-day coefficients of variations did not exceed 3%. The limit of detection 
(LOD) value for fenofibrate was 15ng/ml, and the limit of quantitation (LOQ) value was 
50ng/ml, respectively. The accuracy of the method was verified with recovery values of 98-
102%. 
2.3.4. Characterization of FBT SLN: 
2.3.4.1 Micromeritics measurement: 
The mean particle size and polydispersity index (PDI) of the developed SLN were determined by 
using Zetasizer Nano ZS (Malvern, USA). Dynamic Light Scattering technique was used to 
measure particle size. This technique measures the diffusion of particles moving under Brownian 
motion, and converts this to size and a size distribution using the Stokes-Einstein relationship. 
The mean value of three repeated measurements for each sample was reported as the final 
measurement. SLN sample was diluted with sufficient water and diluted sample were directly 
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placed into cuvette and mean particle size and polydispersibility index were measured [26-28]. 
Zeta potential measurement was carried out with the same instrument Zetasizer Nano ZS. All 
results are an average of three measurements, which are calculated based on an average of 10 
runs. Zeta potential is defined as a measure of degree of repulsion between charged particles. 
These repulsive forces prevent the particle aggregation and are therefore an indicator of physical 
stability of the formulation. According to the literature dispersion with the zeta potential more 
than ± 20 mV is physically stable [29]. The parameters for zetasizer were set as scattering angle 
was 173°, refractive index was 1.33, viscosity was 0.89 cP and the temperature was 25 °C.  
2.3.4.2 Encapsulation efficiency measurement: 
For the determination of the percentage entrapment efficiency, the SLN were first separated from 
the aqueous suspension medium by ultrafiltration-centrifugation using centrifugal filters 
(Amicon Ultra – 0.5 with 50 kDa cut-off, Millipore, USA) at 12000 rpm for 20 min at the room 
temperature. The percent entrapment efficiency was determined in triplicate indirectly by 
determining the amount of free FBT in the aqueous phase of the dispersion. The analysis of FBT 
was performed amount of free FBT in aqueous phase was measured by validated HPLC method 
at wavelength 288 nm. The separation of FBT was performed on a 250 × 4.6 mm BDS hypersil 
C18 column at 40 °C, eluted with water and acetonitrile (25:75; pH adjusted to 2.6 with o-
phosphoric acid) at a flow rate of 1.0 ml/min. The FBT entrapment efficiency (EE) of SLN was 
calculated from the amount of drug determined by the HPLC analysis using the following 
equations, 
                                                Total amount of FBT loaded − Free FBT in supernatant 
Entrapment efficiency   =       ------------------------------------------------------------------ x 100 
                                                                         Total amount of FBT loaded 
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2.3.5. Quantification of drug release in-vitro: 
Dissolution tests for the crude FBT and the marketed micronized FBT formulation (200 mg) 
were performed with a dissolution apparatus using the paddle method. The accurately weighed 
amount of crude FBT (200 mg filled in gelatin capsules) and marketed FBT formulation were 
placed in 900ml phosphate buffer pH 7.4 containing 0.3% sodium lauryl sulfate (SDS) at 37 °C 
and 75 rpm. An aliquot of 1.5 ml release media was withdrawn at intervals of 5, 10, 15, 30, 45, 
60, 90, 120, 180, 240 and 300 min, and then replaced by 1.5 ml of fresh dissolution fluid. Each 
sample was passed through a 0.45 µm syringe filter and determined by HPLC (see section 2.3.5). 
The drug release from SLN formulations was performed by using the dialysis bag technique. 
This is the most exclusively used method reported in the literature to estimate drug release from 
the SLN. We are using dialysis bag method as previously used for studying drug release kinetics 
of nanoparticulate systems by Luo et al. [30] with some modifications. Phosphate buffer pH 7.4 
containing 0.3% SDS was used as the release medium. The dialysis bag retains nanoparticles and 
allows the free drug into the dissolution media with a cut-off of 10–14 kDa. The bags were 
soaked in double-distilled water for 12 h before use. Two milliliters of SLN dispersion was 
poured into the bag with the two ends fixed by clamps and immersed in 50 mL of pre-heated 
release medium in conical flask. The conical flasks were placed into a reciprocal shaking water 
batch manufactured by Precision (Cat. No 51221080) at 37 °C at a rate and 150 rpm. At fixed 
time intervals (Same time points which used for the dissolution of crude FBT and marketed 
formulation), the medium in the conical flask was removed and filtered for analysis and fresh 
dissolution medium was then added to maintain sink condition. The amount of drug in the filtrate 
was analyzed by HPLC method as described above.  Measurements for all three crude FBT, 
marketed formulation and SLN formulation were performed in triplicate and averages are 
reported here. 
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2.3.6. Comparison between the SLN prepared by conventional method and novel HME-
HPH method: 
From PB design, three optimized formulations PB 7, PB 8 and PB 9 were selected and prepared 
by a conventional method as described earlier by Shengpeng et al [31]. Briefly, in conventional 
method lipid and drug heated up to temperature 10-15 °C above the melting point of lipid and 
drug. Surfactants were dissolved in beaker with water, and then added into melted drug and lipid 
drop by drop over 70–80 oC water bath. The obtained pre-emulsion was passed through a high 
pressure homogenizer. These three formulations were compared for characteristics such as PS 
PDI and ZP when prepared by conventional and by novel HME-HPM techniques.  
2.3.7. In-vivo pharmacokinetic study: 
All animal care and experimental studies were approved by the Institutional Animal Care and 
Use Committee (IACUC) with protocol no. 14-013. Jugular vein cannulated male Wistar rats 
(body weight 250 ± 10 g, Harlan laboratories, Indiana, USA) were housed in cages for a 
minimum of at least three days prior to begin of the study and had free access to food and water. 
Rats were randomly divided into three groups of six animals each. The rats were fasted for 12 h 
prior to experiments and after 2 h of dosing of formulations gave access to food. The oral dose of 
FBT was 12.5 mg/animal, thus 0.5 ml formulation was administered to each rat. The crude FBT 
drug was suspended in 0.1% SLS aqueous solution and the commercial micronized FBT 
formulation was diluted 1:10 with saline prior to administration by gavage. The SLN formulation 
was administered undiluted. Serial blood samples (200 µl) was taken from the cannulated jugular 
vein, pre-dose and at time points of, 0.5, 1, 2, 4, 6, 8, 10, 24 h post-dosing. The whole blood was 
collected into heparin coated tubes and centrifuged at 4 °C at 12,000 rpm for 5min to obtain 
plasma. The plasma samples were kept frozen at -80 °C until analysis. 
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2.3.7.1. Plasma processing and HPLC analysis: 
Fenofibric acid was determined by an HPLC-UV method as describe above. The sample 
preparation of the plasma samples was based on the procedure described by Hanafy et al. [20] 
with a little modification. An aliquot of 100 µl plasma and 400 µl methanol was transferred to 
Eppendorf tubes and vortexed for 1 min, followed by the centrifugation at 12,000 rpm for 10 min 
at 4 °C. An aliquot of 20 µl supernatant was injected into the HPLC system and the fenofibric 
acid was detected. The standard calibration curve was prepared in plasma similarly as described 
above. The standard curve was obtained, with a correlation coefficient of 0.9998 over the 
concentration range from 0.11 µg/ml to 123.68 µg/ml. The recovery by the described procedure 
was more than 92% in the investigated concentration range. 
2.3.7.2. Data and statistical Analysis: 
The pharmacokinetic parameters were calculated based on a non-compartmental model. The area 
under the concentration-time curve from time zero to time t (AUC0-t) was calculated using 
trapezoidal method. Peak concentration (Cmax) and time of peak concentration (Tmax) were 
obtained directly from the concentration-time profiles. Differences between batches were 
analyzed by one-way analysis of variance (ANOVA) followed by Tukey test. P < 0.05 was 
considered statistically significant. All values were reported as mean of four findings. 
2.3.8. Stability Study: 
The stability of the developed SLN formulation was conducted for 6 months as per International 
Conference on Harmonization (ICH) Q1A (R2) guidelines. The optimized formulation (PB 9 
design) was selected for the stability study. Briefly, samples were stored in the sealed amber 
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colored glass vials at 4 °C and at 25 °C. After 1, 3 and 6 months, the samples were characterized 
with respect to particle size, ZP, PDI, and EE. 
2.4. Results and Discussion: 
2.4.1. Solubility of FBT in lipids: 
The assessment of solubility of drug in the lipid material is the first step in the selection of lipids 
for the formulation of SLN dispersions as solubility of the drug in the lipid is one of the most 
important factors for determining entrapment efficiency (EE) of the SLN. Four lipids with 
different physicochemical properties were selected and results from the solubility studies are 
shown in Table 2.1. Among five lipids, FBT was not completely soluble in Stearic acid, 
Dynasan® 116 and Imwitor® 900K whereas no drug crystals were observed when FBT was 
heated together with Precirol® ATO 5 for all three concentrations tested (10-20 mg). Also when 
FBT was heated with Compritol® ATO 888, no drug crystals were observed for all four 
concentrations tested (10-25mg). This study indicated that EE of FBT in Compritol® ATO 888 
and Precirol® ATO 5 might be more than Dynasan® 116 and Imwitor® 900K. Thus Compritol® 
ATO 888 and Precirol® ATO 5 were selected for the preparation of SLN. 
Table 2.1: Screening of lipids based on solubility of Fenofibrate (‘+’ indicates no drug 
crystal and ‘_’ indicates drug crystal seen at the end of test) 
Lipid mg Fenofibrate/100 mg solid lipid 
 10 15 20 25 
Stearic acid + - - - 
Compritol ATO 
888 
+ + + + 
Precirol + + + - 
Dynasan 114 + + - - 
Imwitor 900K + - - - 
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2.4.2. Formulation of FBT SLN: 
From the preliminary studies, formulation parameters such as DC, SC, LC, ST and LT were 
found to have significant effects on characteristics of the SLN. Also process parameters such as 
screw configuration, BT, ZA and SS were found to have substantial effects. A modified screw 
configuration was selected to prepare all SLN formulations. To study the effect of formulation 
and process parameters, PB design approach was used. Experimental factors and their levels are 
given in Table 2.2 and the experimental design is shown in Table 2.3. 
Table 2.2: Experimental factors and their levels 
Factor Factor Significance Unit Level (-1) Level (+1) 
X1 Drug Concentration % w/w 0.5 1 
X2 Lipid Concentration % w/w 6 8 
X3 Surfactant 
concentration 
% w/w 1.5 3 
X4 Surfactant -- Cremophore EL Tween80 
X5 Screw speed RPM 160 240 
X6 Barrel Temperature C 120 150 
X7 Zone of Liquid addition -- 3 4 
X8 Lipid -- Compritol® ATO 
888 
Precirol® ATO 5 
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Table 2.3: Experimental Design 
PB X1 X2 X3 X4 X5 X6 X7 X8 
1 1 6 3 Tween 80 160 150 4 Precirol 
2 0.5 6 1.5 Tween 80 160 150 4 Compritol 
3 
1 8 3 
Cremophore 
EL 
160 120 4 Compritol 
4 0.5 8 3 Tween 80 160 120 3 Precirol 
5 1 6 3 Tween 80 240 120 3 Compritol 
6 0.5 8 1.5 Tween 80 240 120 4 Precirol 
7 
0.5 6 1.5 
Cremophore 
EL 
160 120 3 Compritol 
8 
0.5 6 3 
Cremophore 
EL 
240 150 3 Precirol 
9 
0.5 8 3 
Cremophore 
EL 
240 150 4 Compritol 
10 
1 8 1.5 
Cremophore 
EL 
160 150 3 Precirol 
11 
1 6 1.5 
Cremophore 
EL 
240 120 4 Precirol 
12 1 8 1.5 Tween 80 240 150 3 Compritol 
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2.4.3. Experimental Design: 
PB designs are screening designs that involve a large number of factors, which result in 
relatively fewer experiments. Observed and predicted values for all four responses are shown in 
Table 2.4. A total of 12 experimental trials involving 8 variables were performed and as shown 
in Table 2.5 the selected response variables exhibited a wide variation suggesting that the 
independent variables had a significant effect on the response parameters chosen.  
 
 
Table 2.4: Actual and predicted value for PS (Y1), PDI (Y2), ZP (Y3) and EE (Y4) 
 
PB Run Particle 
Size 
Polydispersibility 
Index 
Zeta 
Potential 
Entrapment 
Efficiency 
1 397.00 0.385 -33.24 39.13 
2 209.00 0.507 -31.12 51.17 
3 289.00 0.463 -35.02 75.01 
4 462.00 0.576 -24.42 50.28 
5 349.00 0.257 -39.34 60.34 
6 674.00 0.765 -22.38 53.18 
7 245.00 0.296 -34.04 68.84 
8 153.00 0.376 -36.16 62.49 
9 125.00 0.284 -39.28 78.46 
10 542.00 0.534 -19.49 65.08 
11 485.00 0.454 -27.71 62.19 
12 325.00 0.625 -32.82 66.24 
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Table 2.5: Statistical analysis of particle size (Y1), polydispersibility index (Y2), zeta 
potential (Y3) and entrapment efficiency (Y4) results. 
 
 
Parameters 
Particle size 
(Y1) 
Polydispersibility 
Index (Y2) 
Zeta Potential 
(Y3) 
Entrapment 
Efficiency (Y4) 
Coeffici
-ent 
p-
value 
Coeffici
ent 
p-value Coeffici
-ent 
p-
value 
Coeffici
-ent 
p-value 
Constant b0 354.58 0.007 0.46 0.042 31.25 0.047 61.0 0.0002 
DC  (A) 43.25 0.056 -0.01 0.829 0.02 0.981 0.30 0.230 
LC  (B) 48.25 0.039 0.08 0.019 -2.35 0.045 3.67 0.0003 
SC  (C) -58.75 0.020 -0.07 0.032 3.33 0.018 -0.08 0.705 
ST (D) 48.08 0.040 0.06 0.056 -0.70 0.396 -7.64 ˂0.0001 
SS (E) -2.75 0.907 3.752E-
017 
1.0000 1.70 0.095 2.79 0.0008 
BT (F) -62.75 0.015 -0.01 0.7400 0.77 0.357 -0.61 0.0552 
ZA (G) 8.58 0.720 0.16 0.5263 0.21 0.788 -1.18 0.0095 
LT (H) 97.58 0.002 0.06 0.0690 -4.02 0.010 -5.64 ˂0.0001 
 
Y1 = +354.58 + 43.25 * X1 + 48.25 * X2 – 58.75 * X3 + 48.08 * X4 – 2.75 * X5 – 62.75 * X6 + 
8.58 * X7 + 97.58 * X8 ………………….eq. 2 
 
Y2 = +0.46 – 0.0072 X1 + 0.081 * X2 – 0.070 * X3+0.059 * X4 – 0.00833 * X6+ 0.016 * X7 + 
0.055 * X8 ……………….eq. 3 
 
Y3 = +31.25 + 0.018 * X1 – 2.35 * X2 + 3.32 * X3 – 0.70 * X4 + 1.70 * X5 + 0.77 * X6 + 0.21 * 
X7 – 4.02 * X8……………………eq. 4  
 
Y4 = + 61.03 + 0.30* A + 3.67 * X2 – 0.083 * X3 – 7.64 * X4 + 2.78 * E – 0.61 * X6– 1.18 * X7 – 
5.64 * X8………………..eq 5 
The coefficients in Equations (2) - (5) represent the respective quantitative effect of the 
independent variables (X1, X2, X3, X4, X5, X6, X7 and X8) on the response variables (Y1, Y2, Y3 and 
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Y4).  The effect of selected independent variables on EE, PS, PDI and ZP is graphically 
represented from Fig. 2.4-2.7, respectively. 
 
 
Fig 2.4: Contour plot of EE vs Lipid conc., Surfactant conc., Zone of liquid addition, Screw 
speed and Barrel temp. (Red color indicates the higher EE, yellow indicates less EE and 
Blue color indicates lowest EE) 
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Fig 2.5: Contour plot of PS vs Lipid conc., Surfactant conc. and Barrel temp. (Dark blue 
color indicates the smaller PS and light blue color indicates larger PS) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.6: Contour plot of PDI vs Lipid conc., Surfactant conc., Zone of liquid addition and 
Barrel temp. (Color change from Blue to Green indicates increase in PDI) 
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Fig 2.7: Contour plot of ZP vs Lipid Conc., Surfactant conc., Screw speed, Zone of Liquid 
addition and Barrel temp. (Color change from Red to Green indicates increase in ZP) 
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2.4.4. Effect of Drug Concentration: 
The drug concentration was varied at two levels viz., 0.5 and 1 g. As shown in equations (2, 4 
and 5), drug concentration had positive coefficients for PS, ZP and EE but the p value for the 
drug concentration was found to be more than 0.05 indicating that the drug concentration had 
insignificant effects on all four responses: PS, PDI, ZP as well as EE. This could be due to the 
high solubility of FBT in both lipids Compritol® ATO 888 and Precirol® ATO 5, which might 
result in less variations in the viscosity of the oily phase and therefore there is lower shear 
generated inside the extruder barrel. Increasing drug concentration results in the increase in drug-
to-lipid ratio, which usually decreases EE. Surprisingly, our results showed that increasing drug 
concentration did not decrease the EE of the drug.  This may be due to the range of drug 
concentration we have used in the formulation. The concentration range from 0.5-1% w/w may 
be solubilizing the drug completely into the lipid and therefore there is no decrease in EE, as was 
observed. It may possible that if we increase drug concentration beyond 1% w/w we might see 
decrease in EE of the drug. 
2.4.5. Effect of Surfactant Concentration: 
Concentration of surfactant demonstrated a significant influence on particle size and PDI. As 
shown in eq. (2) the negative value of the coefficient for the surfactant concentration indicates 
particle size and PDI was decreased with an increase in SC. This might be due to the production 
and stabilization of smaller lipid droplets at higher SC as enough surfactant was present to 
reduce interfacial tension between two immiscible phases and stabilize the nano-droplets. Similar 
results were also reported earlier by Das et al, Hu et al and Liu et al [26, 32, 33].  SC had a 
significant effect (p ˂ 0.05) on ZP. Eq. 5 gives the positive coefficient for SC indicating an 
increase in SC increases ZP. Generally SC exhibits a huge influence on entrapment efficiency. 
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As described earlier in Z. Rahman et al [34], a higher amount of surfactant increases the 
solubility of the drug in the external phase and might be increasing the partitioning of drug from 
the internal phase to the external phase. Therefore, generally entrapment efficiency increases 
with an increase in SC as the presence of sufficient SC, which helped the drug to remain within 
the lipid particles and/or the surface of the particles [26]. Surprisingly, we found that the SC had 
a negative coefficient but p-value was more than 0.05 indicating SC demonstrated an 
insignificant effect on EE (as shown in eq. 5). 
2.4.6. Effect of Lipid concentration: 
Lipid concentration did show a significant effect on all four responses: PS, PDI, ZP and EE. 
Particle size significantly increased with increasing lipid concentration. Presence of high lipid 
concentration results increase in the viscosity of the drug-lipid melt. This viscosity increase 
might cause less homogenization during the initial phase of emulsification and produce larger 
particles and larger PDI. The negative coefficient of lipid concentration from eq. 4 indicates an 
increase in LC decreases the ZP of the SLN formulation. This may be due to the negative charge 
of the lipid. As the amount of negatively charged lipid increases in the formulation, the ZP of 
formulation decreases. As expected, EE significantly increased with increasing LC. This might 
be due to availability of a higher amount of lipid to encapsulate more drug, which led to higher 
EE. 
2.4.7. Effect of different surfactant: 
Choice of surfactant showed a significant effect on particle size of SLN. Positive coefficient for 
ST indicates changing ST from Cremophore EL to Tween 80 increases the particle size. 
Cremophore EL produces SLN with smaller particle size than Tween 80. Similar observations 
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are reported by other researchers Das et al [26]. This might be due to the difference in HLB 
value of Cremophore EL and Tween 80. HLB value of 1 and 2 for Compritol® ATO 888 and 
Precirol® ATO 5, respectively, are closer to the HLB of 12-14 for Cremophore than HLB of 15 
for Tween 80.  ST showed a huge effect on EE. As mentioned previously, surfactant increases 
the solubility of the drug in the external phase and might be increasing the partitioning of drug 
from the internal phase to the external phase. As shown in eq. 5, the negative coefficient for ST 
indicates that changing ST from Cremophore EL to Tween 80 decreases EE. This may be again 
due to the high HLB value of Tween 80. EE was significantly low when Tween 80 was used. 
2.4.8. Effect of screw speed: 
Screw speed produced an insignificant effect (p ˃ 0.05) on PS, PDI and ZP. On the other hand it 
exhibited a significant effect on EE. The positive coefficient for screw speed indicates increase 
in speed results in the increase in EE. High screw speed generates higher shear inside the barrel, 
which might result in more homogenization causing more interaction of drug, lipid and 
surfactant resulting in the formation of a homogeneous emulsion. Thus this may explain the 
increase in EE. 
2.4.9. Effect of barrel temperature: 
Barrel temperature only affected particle size of the SLN.  The negative coefficient of barrel 
temperature for particle size demonstrated that increasing barrel temperature reduces the particle 
size of SLN. This might be because with high barrel temperature, it is possible that the lipids and 
drug are completely melted resulting in a low viscosity melt without any solid particles. Barrel 
temperature (zone 2) had insignificant effects on PDI, ZP and EE of SLN.  
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2.4.10. Effect of zone of liquid addition: 
Zone of liquid addition showed an insignificant effect on PS, PDI and ZP. Surprisingly, however, 
ZA demonstrated a very significant effect (p = 0.0095) on entrapment efficiency. Negative 
coefficient for ZA indicates changing zone of liquid addition from zone 3 to zone 4 decreases 
EE. This is may be due to the difference in temperature of molten mass at zone 3 and zone 4. The 
temperature of the molten mass is higher in zone 3 than zone 4 which could affect mixing of the 
molten mass with the surfactant aqueous solution and droplet formation. Also the other reason to 
decrease EE by changing the zone of liquid addition could be the length of mixing elements 
inside the barrel from zone 4 to die is less as compared to the mixing elements from zone 3 to die 
(Fig. 1.2). If we add surfactant solution at zone 3 then the molten mass of lipid-drug and 
surfactant solution are exposed to a larger mixing zone, which generates high shear and may 
enhance entrapment of drug inside the molten lipid. Addition of surfactant solution at zone 4 
provides less exposure to the molten lipid-drug mass for mixing with the surfactant solution. 
Therefore, addition of liquid at zone 4 results in a decrease in EE (39.8%).  
2.4.11. Effect of different lipid: 
Different lipids exhibited a positive impact on particle size and Compritol® ATO 888 produced 
smaller SLN when used as the lipid. This may be due to the variations in melt viscosity of 
Compritol® ATO 888 and Precirol® ATO 5. The positive coefficient for LT for PDI indicates 
low PDI obtained with Compritol® ATO 888 than Precirol® ATO 5 but p-value for LT was 
found to be more than 0.05 indicating an insignificant effect on PDI. EE was found higher in the 
case of Compritol® ATO 888 as compared to Precirol® ATO 5. These observations can be 
explained by the solubility study that demonstrated the higher solubilization capacity of 
Compritol® ATO 888 for FBT. 
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2.4.12. Quantification of drug release in-vitro: 
As aqueous solubility of FBT is very low, 0.3 % SDS was added to the release media to maintain 
the sink condition. In-vitro release of FBT from the optimized formulation (PB 9) was compared 
with the release of pure drug and the marketed micronized FBT formulation for a period of 5 h. 
The amount of FBT released from the SLN dispersion was determined by an in-vitro dialysis bag 
technique. The dialysis bag retained the SLN particles; drug released from SLN and diffused 
through the dialysis membrane into the release media. In-vitro drug release studies (Fig. 2.8) 
showed approximately 94% drug was released at the end of 5 h for FBT SLN formulation (PB 9) 
and 62% for the marketed micronized FBT formulation at the end of 5 h, whereas 41% drug was 
released from pure FBT at the end of 5 h. The increase of the dissolution rate of SLN FBT could 
be mainly attributed to the obvious reduction of the particle size (from a few microns for the 
crude FBT and marketed micronized formulation to a few nanometers (125 nm) for SLN). 
According to Nernst-Noyes-Whitney equation, which described the dissolution rate of drug in a 
diffusion-controlled process, an increase in the surface area could result in an increase in 
dissolution rate [34-37]. 
 
 
 
 
 
 
Fig 2.8: Dissolution profile of FBT SLN prepared by novel HME-HPH method marketed 
micronized FBT formulation (Lofibra) and crude FBT. 
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2.4.13. Comparison between novel HME-HPH method and conventional method for the 
preparation of SLN: 
The particle size, PDI and ZP of the SLN produced using the novel HME-HPH method and 
conventional method are presented in Fig. 2.9 (A, B and C).  The pre-emulsion prepared by 
HME and the conventional method compared with each other are emphasized as this is the major 
contributing difference in these two methods. The quality of the pre-emulsion affects the quality 
of the final product attributes to a large extent and it is desirable to obtain droplets in the size 
range within a few micrometers. Pre-emulsions prepared by both the novel method and the 
conventional method were characterized for PS, PDI and ZP. Particle size of the pre-emulsion 
prepared by the conventional method was 1643 nm whereas the PS was 653 nm when prepared 
by the novel method (Table 2.6). It is apparent that if the initial pre-emulsion particle size is 
significantly higher that it will take more cycles and pressure in the HPH to reduce the particle 
size to 150-200 nm. However, the particle size of the pre-emulsion prepared by the novel method 
is itself in nanometers; less downstream processing in the HPH is required. With this novel 
HME:HPH method high pressure-induced drug degradation that could be caused by HPH can be 
prevented because of the requirement of fewer number of cycles as well as lower pressure as 
compared to the conventional SLN preparation method. 
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Fig 2.9: Particle size (A) Polydispersibility index (B) and Zeta potential (C) of SLN 
produced by novel HME-HPH method and conventional method. The error bars in graph 
indicate 95% confidence interval. 
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Table 2.6: Comparison between pre-emulsion qualities prepared by HME and conventional 
method 
 
 
 
 
 
 
 
2.4.14. In-vivo pharmacokinetic study: 
In order to determine whether the increase in the dissolution rate helps to improve the oral 
bioavailability, an in-vivo experiment was conducted in the fasted state. The pro-drug FBT, 
which contains an ester group, undergoes rapid hydrolysis to produce fenofibric acid by 
intestinal, plasma and tissue esterase, following oral administration. Thus, in the present study 
the pharmacokinetic analysis of FBT is based on the plasma concentration of fenofibric acid. The 
plasma drug concentration-time profiles of FBT after oral administration of various formulations 
to male Wistar rats is shown in Fig. 2.10. The related pharmacokinetic parameters are 
summarized in Table 2.7. At all-time points, the fenofibric acid plasma concentration was 
significantly higher (p < 0.05) for the rats treated with fenofibrate-SLN than the marketed and 
crude fenofibrate. The Cmax value of fenofibrate SLN (65.3 ± 7.2 µg/ml) was higher than the 
marketed (38.05 ± 5.8 µg/ml) and crude fenofibrate (20.0 ± 3.5 µg/ml). Twenty-four hours after 
oral administration, the fenofibrate-SLN plasma concentration was 10 µg/ml which was higher 
as compared to the marketed formulation (4 µg/ml) and crude fenofibrate (3 µg/ml).  From these 
results, one can conclude that fenofibrate absorption was enhanced significantly by employing 
the SLN formulations compared to the marketed and crude fenofibrate [38, 39]. The most 
No. Method 
Particle size 
(nm) 
PDI 
Zeta Potential 
(mV) 
1 HME 653 0.63 -24.1 
2 Conventional method 1643 1.21 -8.2 
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important advantage of SLN formulations over the crude fenofibrate is the lipid protection of 
drug from chemical as well as enzymatic degradation, thus further delaying the in-vivo 
metabolism by oxidative and conjugative pathways. An increase in the rate of drug absorption 
from the SLN has been demonstrated compared to the both marketed micronized formulation 
and crude drug suspension. Reduction in particles size from the micro- to nanometer range 
increases the surface area and thus increases the dissolution velocity according to the equation of 
Noyes-Whitney [40, 41]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.10: Average plasma concentration-time profiles of fenofibric acid following oral 
administration of 50mg/kg in the rat. Three different formulations were tested: SLN 
prepared by novel HME-HPH method, marketed micronized FBT formulation (Lofibra) 
and Crude FBT (means ±S, n=4).  
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Table 2.7: Pharmacokinetic parameters of FBT formulations in Wistar rats (dose 50 
mg/kg, n=4, mean ±SD) 
 
* p < 0.05 compared with crude FBT 
#p < 0.05 compared with Marketed FBT  
 
2.4.15. Stability study: 
Stability results are shown in Table 2.8. Particle size, PDI and zeta potential studies revealed no 
significant change (p > 0.05). Particle size increased after 6 months storage at 25 °C. Although, 
not a significant change in particle size. A slight reduction in entrapment efficiency of the FBT 
SLN was observed after 6 months storage at 25 °C and at 4 °C. However the changes were not 
significant. Thus it can be concluded that FBT SLN have good physical stability in terms of 
particle size, PDI, ZP and EE when stored at 4 °C and 25 °C for the 6 month study period. 
 
 
 
Parameters SLN Formulation Crude FBT Micronized 
marketed 
FBT formulation 
Tmax (h) 4.42 ± 0.4*# 6.9 ± 0.54 6.5 ± 0.4 
Cmax (µg/ml) 65.25 ± 7.2*# 20.0 ± 3.5 38.05 ± 5.8 
AUC0-24 (h.µg/ml) 648.23 ± 85.4
* 266.17 ± 40.9 430.97 ± 70.0 
AUMC0-24h 
(µg-h2/ml) 
5342.17 ±  527.2*# 2306.74 ± 221.1 3509.26 ± 324.1 
MRT0-24 (h) 8.24 ± 0.5 8.66 ± 1.4 8.14 ± 0.7 
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Table 2.8: Stability after 6 months storage at 4 °C and 25 °C (data represent mean ±SD) 
(PB 9 Formulation) 
 
2.5. Conclusion: 
The current study demonstrates that our novel process based on HME-HPH of SLN production is 
an appropriate continuous technology for producing nano-formulations. The proposed method of 
HME-HPH was found to be suitable for continuous production of SLN using QbD principles and 
a DOE approach. This continuous, single step method was found to be a potentially economical, 
as well as an efficiency benefit for the production of SLN. In addition the process aids to 
minimize issues associated with the conventional methods of SLN preparation such as pressure-
induced drug degradation. Findings of this study demonstrated that selected independent 
variables significantly affects critical quality attributes of the SLN. Thus, these outcomes of this 
research have successfully demonstrated the application of QbD principles and a DOE approach 
to develop a continuous process of SLN production via the HME-HPH technique. 
 
 
Storage Particle Size 
(nm) 
PDI Zeta Potential 
(mV) 
Entrapment 
Efficiency (%) 
 4 °C 25 °C 4 °C 25 °C 4 °C 25 °C 4 °C 25 °C 
Fresh 125 ± 0.16 0.284 ± 0.032 39.28 ± 1.21 78.46 ± 1.42 
1 
month 
124.2 
±0.4 
128 
±0.1 
0.286 
±0.04 
0.284 
±0.04 
39.04 
±1.7 
38.23 
±1.4 
78.13 
±1.3 
77.92 
±1.4 
3 
month 
127 
±0.3 
133 
±0.5 
0.292 
±0.1 
0.293 
±0.02 
37.74 
±1.5 
36.12 
±1.2 
77.48±1
.9 
75.14 
±1.2 
6 
month 
132 
±0.3 
139 
±1.4 
0.301 
±0.1 
0.302 
±0.02 
37.22 
±1.3 
35.12 
±2.4 
76.23 
±2.1 
73.47 
±1.5 
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CHAPTER III 
 
FORMULATION AND DEVELOPMENT OF PH-INDEPENDENT/DEPENDENT 
SUSTAINED RELEASE MATRIX TABLETS OF ONDANSETRON HCL BY 
CONTINUOUS TWIN-SCREW MELT GRANULATION PROCESS 
3.1. Abstract 
The objective of the present study was to develop pH-independent/dependent sustained release 
(SR) tablets of ondansetron HCl dihydrate (OND), a selective 5-HT3 receptor antagonist that is 
used for prevention of nausea and vomiting caused by chemotherapy, radiotherapy and 
postoperative treatment. The challenge with the OND API is its pH-dependent solubility and 
relatively short elimination half-life. Therefore, investigations were made to solve these 
problems in the current study. Formulations were prepared using stearic acid as a binding agent 
via a melt granulation process in a twin-screw extruder. The micro-environmental pH of the 
tablet was manipulated by the addition of fumaric acid to enhance the solubility and release of 
OND from the tablet. The in vitro release study demonstrated sustained release for 24 h with 
90% of drug release in formulations using stearic acid in combination with ethyl cellulose, 
whereas 100% drug release in 8 h for stearic acid-hydroxypropylcellulose matrices. The 
formulation release kinetics was correlated to the Higuchi diffusion model and a non-Fickian 
drug release mechanism. The results of the present study demonstrated for the first time the pH 
dependent release from hydrophilic-lipid matrices as well as pH independent release from 
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hydrophobic-lipid matrices for OND SR tablets manufactured by means of a continuous melt 
granulation technique utilizing a twin-screw extruder. 
3.2. Introduction 
Several approaches has been used to develop sustain release (SR) matrix formulations and 
among them the most interesting approach is based on melt granulation techniques. Melt 
granulation is a process by which pharmaceutical powders are efficiently agglomerated by the 
use of a low melting point binding material, which after melting act as a binding liquid [42]. The 
advantage of this process over other techniques is that it is a solvent free process, and thus there 
is no need for a drying step, which consumes time and energy. Also, the percent of fines 
produced by the melt granulation process is less as compared to the wet and dry granulation 
process [43]. Several researchers have used melt granulation processes using different kinds of 
low melting point excipients as binders (polyethylene glycols 3000, 6000 and 8000, various 
types of waxes and lipids) [44-46]. Over the last few years several techniques have been 
investigated for melt granulation processes such as high-shear granulation, fluidized bed 
processing and others. [47, 48]. Hot melt extrusion (HME) is another thermal processing 
technique that has attracted interest as a novel technique for melt granulation [46, 49]. HME is a 
continuous, simple, easy to scale up and efficient process [5, 7, 50]. 
Nausea and vomiting are the common problems in cancer patients undergoing chemotherapy, 
radiation therapy, and postoperative treatment or due to the advancement in cancer itself. 
Serotonin (5-Hydroxytryptamine) subtype-3 (5-HT3) receptor plays an important role in 
emetogenic pathways in relation to massive release of serotonin from damaged enterochromaffin 
cells in the gastrointestinal tract following chemotherapy [51, 52]. Serotonin antagonists exert 
their anti-emetic action via 5-HT3 receptors located centrally (chemoreceptor trigger zone of the 
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area postrema and nucleus tractus solitaries) as well as peripherally (enterochromaffin cells of 
the enteric nervous system) [53, 54]. 5-HT3 receptor can be antagonized by drugs such as 
ondansetron, tropisetron, granisetron, dolasetron, palonosetron and ramosetron as well as by 
certain drugs having prokinetic (increasing gut motility) action such as renzapride, cisapride and 
metoploramide [52, 55]. 
Ondansetron, a carbazole derivative, is a potent, highly selective competitive 5-HT3 receptor 
antagonist [56]. Intravenous and oral dosage forms of OND are commercially available, for 
example: oral solutions, orally disintegrating tablets and film-coated tablets. The recommended 
oral dose regimen of OND is 8 mg, three times a day. Following oral administration OND is well 
absorbed from the GIT and its bioavailability is approximately 67% and the elimination half-life 
is relatively short, approximately 3-5 h [57, 58].  
The present study has investigated HME techniques to prepare OND granules. Stearic acid is 
commonly used as a tablet lubricant in oral formulations. Also it has been extensively explored 
as a binder. In the current study, stearic acid is used as a melt binder in the formulations. Two 
different polymers were used as matrix formers such as the water-insoluble and almost un-
swellable ethyl cellulose [59], and the water-soluble and swellable hydroxypropyl cellulose 
(HPC) in combination with stearic acid. OND exhibits pH dependent solubility and therefore, it 
is freely soluble in gastric fluid’s low pH [60], but practically insoluble at pH > 6. Several 
approaches have been used in the past to overcome pH–dependent solubility of weakly basic 
drugs [61]. The commonly used approach is the addition of acid pH modifiers to the matrix 
tablets [62]. Therefore, based on preliminary studies, these investigators have used fumaric acid 
to create a suitable micro-environmental pH, which increased drug solubility at higher pHs.  
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At present commercially available orodispersible as well as conventional OND tablets are meant 
for immediate release of the drug and are given 3-4 times a day due to the short half-life (3-5 h) 
of OND. Therefore, there is a need to develop a sustained release formulation for OND which 
exhibits pH-independent release profile. The aim of this novel study was to 1. Develop an 
innovative sustained release OND tablet by continuous twin-screw melt granulation processing. 
2. To investigate the influence of formulation parameters on the physical properties of the hot-
melt extruded granules and compressed tablets containing stearic acid as a release-retarding 
agent 3. Study the release kinetics for OND tablets prepared by either hydrophilic or 
hydrophobic polymers in combination with stearic acid. 4. To study the effect of fumaric acid on 
drug release behavior from the tablet matrix. 
3.3. Materials and methods 
3.3.1. Materials 
Ondansetron HCl Dihydrate was purchased from Chemscene LLC (New Jersey, USA). 
Hydroxypropyl cellulose (Klucel® EF) was kindly gifted by Ashland Specialty Ingredients. 
(Wilmington, DE). Ethyl cellulose (Ethocel® Standard 10) was gifted from Dow chemical 
company. Fumaric acid and Magnesium stearate was purchased from Spectrum Laboratory 
Products Inc. (Gardena, CA). Microcrystalline cellulose (Avicel® PH 101) was gifted from FMC 
Biopolymer (Philadelphia, PA). Stearic acid was purchased from EMD Millipore (Billerica, 
MA). All the other reagents such as methanol (impurities ˂ 0.1%) used in this study were of the 
analytical grade.   
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Table 3.1: Compositions of the investigated granules (all quantities given in percentile) 
*Magnesium stearate (0.3%) added in all batches extra granularly before compression. 
3.3.2. Compatibility of OND with different excipients 
 To study the compatibility of OND with the polymers and other excipients, physical mixtures 
were prepared by mixing the drug with each formulation excipients in the ratio of 1:1. Pure drug 
(OND) and two physical mixtures were characterized by differential scanning calorimetry 
(Diamond DSC, Perkin Elmer) using Pyris manager software (PerkinElmer Life and Analytical 
Sciences, 719 Bridgeport Ave., CT, USA) and Fourier transform infrared spectroscopy (Agilent 
Formulation OND EC HPC SA FA Magnesium 
Stearate 
MCC 
F1 20 37 __ 12 __ 0.2 30.5 
F2 20 __ 37 12 __ 0.2 30.5 
F3 20 37 __ 12 2.5 0.2 28 
F4 20 37 __ 15 2.5 0.2 25 
F5 20 40 __ 12 2.5 0.2 25 
F6 20 40 __ 15 2.5 0.2 22 
F7 20 __ 37 12 2.5 0.2 28 
F8 20 __ 37 15 2.5 0.2 25 
F9 20 __ 40 12 2.5 0.2 25 
F10 20 __ 40 15 2.5 0.2 22 
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Technologies Cary 660, Santa Clara, CA). For the DSC study, samples were prepared by sealing 
3-5 mg of pure API and physical mixture in hermetically sealed aluminum pans and the thermal 
analysis was performed under an inert nitrogen atmosphere at a heating rate of 10 °C/min over a 
temperature range of 40-250 °C. FTIR studies were conducted in the range of 4000-400 cm-1. 
The bench was equipped with an ATR (Pike Technologies MIRacle ATR, Madison, WI), which 
was fitted with a single bounce diamond coated ZnSe internal reflection element.                          
3.3.3. Hot melt granulation 
Ondansetron HCl dihydrate (20% w/w) was blended with other excipients as shown in Table 3.1 
using a V-shell blender (GlobePharma, MaxiblendTM New Brunswick, NJ) for 20 min at 25 rpm, 
after passing through US# 35 mesh screen to remove any aggregates that may have formed. Hot 
melt granulations were processed without an extrusion die in a fully intermeshing co-rotating 
twin screw extruder (11 mm Process 11TM Thermo Fisher Scientific) with modified screw design 
(Figure 3.1). This extruder barrel consists of a total of 8 zones. The first zone (no heating), also 
known as feeding zone, is where the physical mixture is fed. Based on the preliminary studies 
zone 2 and zone 3 were set at 110 °C, zone 4 was set at 70 °C and the remaining subsequent 
zones (zone 5 – zone 8) were heated to 50 °C. The set temperatures of all zones were below the 
melting point of OND (189 °C). The modified co-rotating screw configuration consists of mixing 
elements at two places, one at zone 3 and second before the discharge elements. The extruder 
was allowed to equilibrate at set temperature for 30 min before starting the trials. The physical 
mixtures were loaded into the volumetric feeder, fed from the extruder feeding zone and further 
processed through extruder barrel at the set temperatures. Powder feed rate (7.2 g/min) and screw 
speed (100 rpm) were selected from the preliminary data and kept constant for all batches. 
Granules were collected from the open end of the extruder after steady state was reached for a 
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trial condition. At the end of the granulation process the collected granules were stored in a foil-
lined sealed bag. 
 
Fig 3.1: Modified screw configuration 
3.3.4. Micromeritic properties of granules 
Bulk density was calculated by measuring the volume of 5 g granules in a 10 ml graduated 
cylinder. The cylinder was tapped 100 times until no further reduction in the volume of the 
granules was observed. Tapped density was calculated using the volume of the granules after 
tapping. Flow properties of the granules such as angle of repose, Carr’s index, and Hausner’s 
ratio were also calculated. The angle of repose was determined by the funnel method. The 
accurately weighed powder was placed in a funnel. The height of the funnel through which the 
powder passes was adjusted in such a way that the tip of the funnel just touched the tip of the 
cone of the powder. The powder was allowed to flow through the funnel freely onto the fixed 
base. The diameter of the powder cone and height of the cone was measured. The angle of repose 
(Ɵ) was calculated using the following equation: 
                                                          Tan (θ) =
ℎ
𝑟
                           
Where ‘h’ and ‘r’ are the height and radius of the powder cone respectively. 
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Carr’s (compressibility) index [63] and Hausner’s ratio (HR) was determined according to the 
following formula: 
                                                 CI =  
(Tapped density−Bulk density)
Tapped density
 × 100 
 
                                                      HR =  
Tapped density
Bulk density
 
3.3.5. Particle size distribution 
Particle size distribution was analyzed by the sieve analysis method. Two standard sieves 
(U.S.A. Standard Test Sieve) with mesh sizes of 500 µm and 1400 µm were used to conduct the 
sieve analysis. Three fractions were collected, that is, granule size more than 1400 µm, granule 
size in-between 1400 - 500 µm and granule size less than 500 µm which are considered as fines 
and the percentile weight distribution was determined for all three fractions. 
3.3.6. Tablet compression 
Prior to direct tablet compression, granules were mixed with 0.3% magnesium stearate. Tablets 
were manually prepared by direct compression on a single punch tablet press (MCTMI, 
GlobePharma Inc. New Brunswick, NJ), by using an 8 mm flat round punch at a compression 
force of 130 kg/cm. 
3.3.7. Evaluation of tablet properties 
Compressed tablets were evaluated for hardness, thickness, friability and drug content 
uniformity. Ten tablets were randomly selected and tested for their hardness (Hardness tester, 
Schleuniger). An additional ten tablets were randomly selected and tested for their thickness 
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using a digital Vernier caliper (Montana). The friability was determined as percentage weight 
loss of tablets (weighing 6.5 g) using a dual scooping projection Vander Kamp friabilator 
(Vankel Industries Inc. Chatham, NJ) for 4 minutes at 25 rpm. 
3.3.8. Evaluation of Gel Layer pH 
To study the effect of fumaric acid, the pH of the tablet surface was measured within 10 h by an 
Oakton pH meter (pH Spear, Fisher Scientific) equipped with a contact electrode. The 
dissolution media used to conduct this test was 0.1N HCl (pH 1.2) for the first 2 h, followed by 
pH 6.8 buffer for the remaining 8 h. The tablets were removed at an interval of 1 h to check the 
surface pH up to 10 h [64]. Briefly, the tested tablets were removed from the dissolution vessel at 
set time interval and bathed with purified water to remove residual buffer from the tablet surface. 
Then the contact electrode was slightly pressed into the gel layer of the tablet to measure the pH.  
3.3.9. In-vitro drug release 
In-vitro drug release was measured using USP dissolution apparatus II (Hanson SR8) set at 50 
rpm and equipped with UV-Vis probes (Rainbow Dissolution Monitor, PION) collecting spectra 
every 2 min for the first 2 h and then for every 25 min until 24 h at 305 nm. The test dissolution 
media were 700 ml of 0.1N HCl (pH 1.2) with 1% SLS for the first 2 h, then 200 ml of 0.2 M 
tribasic sodium phosphate (pH 12.5) with 1% SLS to provide a final pH of 6.8 for 24 h (media 
were maintained at 37 ± 0.5 °C) to simulate the tablet transit from stomach (pH 1.2) to the 
intestine (pH 6.8) [63, 65]. The drug release studies were conducted in triplicates and the mean 
values were plotted versus time. 
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3.3.10. Similarity and dissimilarity factor analysis 
The similarity (f2) and dissimilarity (f1) factor was used to evaluate pH-independent release 
patterns of OND from the optimized tablets in the release media pH 1.2 and pH 6.8. Similarity 
and dissimilarity factors are calculated by using the following Eq. [66]: 
ƒ2 =  50 𝑙𝑜𝑔 (
1
√1+ (
1
𝑝
) ∑ (𝑅𝑡−𝑇𝑡)²𝑃𝑖=1
  × 100)                                                                       
  𝑓1 = {[𝑆𝑡=1𝑛 ⃓Rt –  Tt⃓]} × 100 
Here, Rt and Tt are the cumulative percent of drug dissolved from matrices for the references and 
test samples at time t and n is the number of time points. The similarity factor values ranges 
between 0 and 100. The similarity between two profiles increases when f2 value approaches 100, 
whereas dissimilarity occurs with a decrease of the f2 value (less than 50) [67]. 
3.3.11. Drug Release Kinetics and mechanism  
In order to study the mechanism of drug release from the matrix tablets, the experimental data 
was evaluated kinetically by the following equations [64, 68-70], 
Zero order equation: 𝑄𝑡 = 𝑄0 + 𝐾0 𝑡 
First order equation: 𝐼𝑛 𝑄𝑡 = 𝐼𝑛𝑄0 +  𝐾1𝑡/2.303 
Higuchi equation: 𝑄𝑡 = 𝐾𝐻𝑡
1/2 
Korsmeyer-Peppas equation: 
𝑄𝑡
𝑄∞
= 𝐾𝑘𝑝𝑡
𝑛 
where, Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in the 
solution, Q ͚ is the amount of drug released after infinite time, K0 is the zero order release rate 
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constant, K1 is the first order release rate constant, KH is the Higuchi diffusion rate constant, Kkp 
is the release constant comprised of structural and geometrical characteristics of the tablets and 
‘n’ is the release exponent indicating the mechanism of the drug release. 
3.3.12. Statistical Data Analysis 
The differences between batches were analyzed by one-way analysis of variance (ANOVA) 
followed by Student’s t-test. A difference of p ˂ 0.05 was considered statistical significant. All 
values were reported as the mean of three recordings. 
3.4. Results and Discussion 
3.4.1. Compatibility of OND with different excipients 
Drug-excipients compatibility studies were performed utilizing DSC and FTIR. Any abrupt or 
drastic changes in the thermal behavior of either the drug or polymer may indicate a possible 
interaction between drug and polymer. DSC of drug-polymer physical mixture for both EC-SA 
and HPC-SA matrices showed a well recognizable endothermic peak of OND at 181.74 °C, the 
temperature slightly shifted to the lower temperature than corresponding to the melting point of 
the pure drug (188.58 °C). This result indicates that the drug is compatible with the polymer but 
due to the presence of stearic acid which is acting as a plasticizer results in lowering the melting 
temperature of OND. There was no change in the glass transition temperature and melting 
endotherms of other excipients used in the formulation confirming the absence of any drug-
polymer interaction. Also, there were no considerable changes in the IR peaks of OND when 
mixed with other excipients further confirming the absence of drug-excipient interaction. The 
FTIR spectra of the pure drug and physical mixture were compared and the characteristic peak 
for the physical mixture was found to be superimposable to that of the pure drug. This result 
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indicates that there was no drug polymer interaction. A broad band of bonded –OH of OND was 
observed from 3481 cm-1 to 3245.97 cm-1, and a peak of –CH stretching was found at 2900  cm-1 
indicating the presence of a methyl group, and at 1680 cm-1 (-C=O stretching) indicating a keto 
group in all of the formulations’ physical mixtures (Figure 3.2). 
 
Fig 3.2: (a) DSC and (b) FTIR spectra of pure OND, physical mixture for EC-SA matrix 
and HPC-SA matrix. 
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Table 3.2: Granule properties of the different formulations of Ondansetron hydrochloride 
(OND) 
Formulation Angle of 
repose ( °C) 
BD (gm/cm3) TD (gm/cm3) Carr`s 
Index (%) 
Hausner’s 
Ratio 
F1 26 19 16 15.79 1.19 
F2 27 19.5 16 17.95 1.22 
F3 26 20 17.5 12.5 1.14 
F4 27 20 16 20 1.25 
F5 27.5 21 18 14.28 1.17 
F6 28.5 17.5 14.5 17.14 1.25 
F7 27 19 16 15.79 1.19 
F8 28 17 14 17.65 1.21 
F9 28 15.5 13 16.13 1.19 
F10 28.5 18 15.5 13.89 1.16 
 
3.4.2. Micromeritic properties of granules 
Granule flowability and compactability affects the die filling and tablet mechanical 
characteristics; therefore it is essential to study the granule flow properties. Various tests have 
been performed on all formulations such as bulk density, tapped density, angle of repose, Carr’s 
index and Hausner’s ratio. According to the flow property classification of USP, the angle of 
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repose in a range of 25 to 30 indicates excellent flow properties. All the prepared formulations 
showed excellent flowability (25 ˂ angle of repose ˂ 30).  
As shown in Table 3.2, it is clear that as the amount of the meltable binder and polymer 
increased, the angle of repose also increased. Carr’s index and Hausner’s ratio are also the 
measurement of flow properties and good flowing granules should have a Carr’s index between 
10.0 to 18.0%, whereas Hausner’s ratio should be less than 1.25. When the Carr’s index and 
Hausner’s ratio are adequate, the powder flows at minimum bulk density and consolidates to 
maximum density inside the die, prior to compression [71]. Carr’s index and Hausner’s ratio in 
Table 3.2 are between 10.0 to 18.0% and less than 1.25 respectively, confirming the good flow 
of granules obtained in all the formulations. 
 
Fig 3.3: Particle size distributions of the OND granules (F1-F10) (determined by sieve 
analysis)  
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3.4.3. Particle size distribution 
The results of sieve analysis are shown in Figure 3.3. These results were useful to understand the 
effect of the concentration of stearic acid, EC and HPC on the granule size fractions (F), defined 
as fines (F < 500 µm), fraction of interest for tableting (500 µm < F < 1400 µm) being the 
granulation yield, and oversized granules (F > 1400 µm). Large size granules are obtained with 
the increase in the amount of binder stearic acid or polymer, as a result of increase in the cross-
linking inside the matrix granules, which leads to the increase in the matrix density of the 
granules.  
3.4.4. Evaluation of tablets 
The formulated tablets were evaluated for hardness, friability, weight variation, and thickness. 
These parameters were found to be within the acceptable limits as shown in Table 3.3. OND 
content uniformity in the prepared tablets was determined. Briefly, 20 tablets were selected 
randomly and triturated with the help of morter and pestle. The amount equivalent to weight of 
one table was weighed and OND content was determined using UV-Vis Spectrophotometer at 
λmax 305 nm against blank. All of the formulations possessed exceptional drug content (> 98%) 
as well as content uniformities (< 2% RSD) after the melt granulation process. This is indicative 
of a robust formulation and process. 
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Table 3.3: Comparisons of the physical properties of the matrix tablets containing 
Ondansetron hydrochloride 
Formulation Hardness 
(Kp) 
Thickness 
(cm) 
Weight 
(mg) 
Friability 
(%) 
Content 
Uniformity (%) 
F1 6.3±0.07 2.40 150.2 0.32 100.5 
F2 6.2±0.05 2.38 150.3 0.35 100.2 
F3 6.0±0.01 2.37 151.2 0.31 98.46 
F4 6.7±0.06 2.39 149.8 0.30 101.3 
F5 6.2±0.02 2.40 150.3 0.32 101.7 
F6 6.8±0.04 2.37 150.7 0.35 103.4 
F7 5.9±0.03 2.39 151.4 0.31 102.6 
F8 6.6±0.08 2.41 150.9 0.35 99.8 
F9 6.1±0.04 2.40 151.3 0.32 102.4 
F10 6.9±0.03 2.38 151.5 0.36 103.8 
 
3.4.5. Tablet Surface pH measurement using contact electrode 
To determine the effect of fumaric acid on OND solubility and release characteristics, the tablet 
surface pH was measured every hour during 10 h of the study using a pH Spear, Oakton pH 
meter. It was expected that the pH of the tablet surface for all of the samples would be similar to 
the pH value of the dissolution media. For the first 2 h when 0.1 N HCl (pH 1.2) dissolution 
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media was used the tablet surface measured a pH of 1.2-1.4, whereas after 2 h when phosphate 
buffer was added, the dissolution media pH was changed to 6.8, at that time the differences in 
tablet surface pH were observed between samples during different time intervals. Formulation F1 
and F2 (without fumaric acid) indicated pH values the same as pH of the dissolution media (for 
first 2 h in 0.1N HCl the tablet pH was 1.2-1.4, and in HCl-phosphate buffer pH was 6.8-7.0). 
Formulation F3 and F7 (with fumaric acid) measured pH 1.2-1.4 for the first 2 h in 0.1 N HCl 
and after 2 h pH of the tablet surface was changed to 3.5-4.0 in the HCl-phosphate buffer 
dissolution media of pH 6.8 (Figure 3.4). This indicates that fumaric acid is dissolved inside the 
tablet microenvironment and thus maintaining the acidity inside the tablet, which assisted in the 
solubilization of OND in dissolution media with higher pH. 
 
 
 
 
 
 
Fig 3.4: Change of gel layer pH within the dissolution test of the matrix tablets (2 h in 1.2 
and following 2 h pH changes to 6.8). 
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Fig 3.5: In-vitro drug release profile for formulations F3-F10 by two-step dissolution media 
method  
 
 
 
 
 
 
 
Figure 3.6: Effect of pH of surrounding media on OND release from formulations F1 and 
F2  
 
3.4.6. Effect of pH of dissolution media, fumaric acid and different polymer matrices on 
drug release 
In-vitro dissolution studies for all formulations were performed using the two-step dissolution 
method by changing pH, which better corresponds to the real conditions in the gastrointestinal 
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tract (2 h in pH 1.2 and following 22 h in pH 6.8) [64] (Figure 3.5). Also, in-vitro dissolution 
studies were performed in both 0.1 N HCl and pH 6.8 buffer individually to see the effect of 
change in the pH of the dissolution media on drug release. As expected, the pH of the dissolution 
medium was found to significantly affect (p˂0.05) the release rate of OND from the matrix 
system. Figure 3.6 showed a lower percentage of OND release at pH 6.8 as compared with the 
high percentage of OND release in 0.1 N HCl at 24 h, which is due to the very low aqueous 
solubility of OND at basic pH. 
To study the effect of fumaric acid on drug release, in-vitro dissolution studies for formulations 
containing fumaric acid (F3/F7) and formulations without fumaric acid (F1/F2) were conducted 
in both pH 1.2 and pH 6.8 buffer media. Formulation F3 and F4 composition contained fumaric 
acid to create a constant acidic micro-environment inside the tablets. Therefore, irrespective of 
the pH of the surrounding dissolution medium, fumaric acid assisted in the solubilization and 
release of OND (weakly basic drug) in high pH dissolution medium corresponding to the 
intestinal pH. These data contribute to solving the pH-dependent solubility problem of OND. 
Ideally, fumaric acid should dissolve slowly so that it will remain inside the tablet during the 
entire period of drug release. The dissolution results clearly indicated that the presence of 
fumaric acid in the matrices increased the dissolution of OND in phosphate buffer pH 6.8. 
Approximately 90% of drug was released within 24 h from formulation F3 containing fumaric 
acid in both pH 1.2 and pH 6.8 buffer. The maintenance of a constant and low acidic 
microenvironment by fumaric acid created the most favorable conditions for OND release. 
However, formulation F1 and F2 which do not contain fumaric acid demonstrated slower drug 
release in pH 6.8 as compared to that of pH 1.2 media. These observations indicate that the 
presence of fumaric acid inside the tablet may affect initial porosity of the tablet as well as 
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assisting in maintaining the acidic pH inside the tablet, which resulted in the increased drug 
release. To clarify the important role of fumaric acid in the pH-independent/pH-dependent 
release of OND in both gastric and intestinal fluid, dissolution profiles of both EC-SA and HPC-
SA matrix OND tablets containing fumaric acid (F3 and F7) are compared in Figure 3.7. 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.7: Effect of fumaric acid on drug release from a) EC-SA matrix b) HPC-SA matrix 
 
This research group also studied the effect of different types of polymers in combination with 
stearic acid on the drug release profile. It was observed that the release of the drug depends upon 
the type of polymer used in the formulation. Ethyl cellulose (hydrophobic polymer) along with 
a) 
b) 
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stearic acid sustained the drug release over the period of 24 h (90% drug release). However, 
hydroxypropyl cellulose (hydrophilic polymer) in combination with stearic acid sustained drug 
release over a period of 7-9 h (100% drug release) (Figure 3.8). This effect is contributed to the 
nature of polymer in use. The formulations with EC-SA matrices demonstrated a retarded release 
of the drug compared to the more hydrophilic matrices. This may be due to the hydrophobic 
nature of the EC polymer, which prevents the penetration of the dissolution medium into the 
tablet matrix leading to slower dissolution and diffusion of the drug molecules from the matrix 
system. These properties sustain the drug release from the matrix of the tablet for a longer period 
of time as compared to HPC-SA matrix. In formulations with HPC-SA matrices, it was observed 
that the release of the drug was faster. HPC due to its water-soluble nature dissolves faster and 
acts as a channeling agent. In our current study, we have used HPC EF, which has low viscosity 
in water and therefore, it dissolves faster in aqueous media. In the HPC-SA matrix systems, two 
drug release mechanisms are possible. One mechanism is that after coming in contact with 
aqueous media HPC EF are hydrated and swelled resulting in formation of a hydrogel through 
which the dissolved drug diffuses and transfers into the dissolution media. Secondly, dissolution 
of HPC in dissolution media results in a further increase in drug release. Also, due to the 
hydroxyl ion (from pH 6.8 media) fumaric acid is dissolved resulting in more pore formation in 
the HPC matrix as compared to EC-SA matrices. Drug release occurs by mixed mechanisms of 
diffusion and erosion of the matrix [59, 72]. Thus, the HPC-SA system retarded drug release (˂ 
10 h) as compared to EC-SA matrices. 
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Fig 3.8: Effect of type of polymers (ethyl cellulose and hydroxypropyl cellulose) used in the 
formulations on drug release profile by two step dissolution method 
 
The In-vitro study also revealed that the release of drug was retarded with the proportional 
increase in the polymer and binder concentration such as in the case of the EC-SA matrix (Figure 
3.9a). In-vitro drug release decreased from 90% to 64% and 71.9% (F3 to F4 and F5) with the 
increase in polymer or lipid concentration respectively. In formulation F6, where the percentage 
of both EC and SA in the tablet composition was increased, the drug release further reduced to 
58% at the end of 24 h of dissolution study. On the other hand, the increase in the percentage of 
HPC and SA in formulation F10 resulted in faster drug release. Complete drug release was 
obtained within 6.5 h for formulation F10, whereas it was 9.5 h for formulation F7 (Figure 3.9b). 
The drug release mechanism seen here was the combined effect of diffusion and erosion 
processes due to the dissolution of HPC and fumaric acid. 
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Fig 3.9: Effect of concentration of polymers and binder a) ethyl cellulose (37% and 40%) b) 
hydroxypropyl cellulose (37% and 40%) used in the formulation on release of OND by two 
step dissolution method 
 
3.4.7. Similarity and dissimilarity 
Similarity factor (f2) and dissimilarity factor (f1) were calculated using the release profiles of the 
formulations in pH 1.2 and 6.8 to see the effect of fumaric acid, pH of surrounding media, and 
type of polymer used in the formulations.  
As shown in Table 4, f2 value for formulations F1 and F2 in pH 1.2 and 6.8 media were 40 and 
29 and, the f1 values were 36 and 49 respectively. These results indicate that the release profile of 
a) 
b) 
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formulation F1 and F2 were not similar as the f1 value is less that 50 and f2 value is more than 15. 
These data indicate that formulation F1 and F2 exhibited pH-dependent release profiles and 
therefore shows different profiles as change in the pH of the dissolution media. This research 
group also studied the effect of addition of fumaric acid on the similarity and dissimilarity factor. 
f2 value for formulations containing fumaric acid such as F3 and F7 in pH 1.2 and 6.8 were 74 
and 44, whereas f1 value were 6 and 25 respectively, indicating similarity in the dissolution 
profile for formulation F3, whereas slight dissimilarity in F7. The dissolution profiles and f1/f2 
values for formulation F3 confirms that it exhibits pH-independent solubility and pH changes do 
not influence dissolution of this formulation. 
Use of different polymers in the formulation composition illustrated different dissolution 
profiles. As shown in Table 3.4, f2 values for formulations F3/F7 was 41 and f1 values was 36 
confirming the differences in the dissolution profiles.  
Table 3.4: Similarity and Dissimilarity factor analysis 
Formulations Similarity factor Dissimilarity factor 
F1 (pH 1.2 and 6.8) 40 36 
F2 (pH 1.2 and 6.8) 29 49 
F3 (pH 1.2 and 6.8) 74 6 
F7 (pH 1.2 and 6.8) 44 25 
F3/F7 41 36 
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3.4.8. Determination of drug release kinetics 
In order to describe the release behavior of OND from different formulations, the dissolution 
profiles were analyzed according to kinetic equations such as zero-order, first-order, Higuchi and       
Korsmeyer-Peppas. The regression coefficient values of different release kinetic equations for all 
developed formulations were compared as shown in Table 3.5. All batches containing EC in 
combination with stearic acid (F3-F6), showed a very good correlation to the Higuchi equation 
(r2=0.9902-0.9985). The Higuchi plot showed high linearity in comparison to other release 
kinetic equations, which indicates that the drug release is heavily governed by the diffusion 
process. To confirm the diffusional mechanism, the data were fitted into Korsmeyer–Peppas 
equation. As shown in Table 4, release exponent (n) found for batches F3-F6 was less than 0.5. 
Release exponent n˂5 is considered consistent with a diffusion-controlled release, whereas 
values of n between 0.5 – 1 indicates non-Fickian (anomalous) release mechanisms. 
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Table 3.5: Mathematical modeling and release kinetics of OND from the prepared 
formulations (F1-F10) 
 
 
 
 
Formulation 
Zero order 
plot 
Correlation 
coeff. (R2) 
First order 
plots 
Correlation 
coeff. (R2) 
Higuchi’s 
plots   
Correlation 
coeff. (R2) 
Korsmeyer-Peppas plots 
Correlation 
coeff. (R2) 
Diffusional 
exponent (n) 
F1 0.9533 0.1383 0.9897 0.9889 0.42 
F2 0.9249 0.2162 0.9939 0.9929 0.43 
F3 0.9386 0.6328 0.9973 0.9985 0.46 
F4 0.9776 0.2201 0.9914 0.9908 0.39 
F5 0.9617 0.3551 0.9992 0.9959 0.45 
F6 0.9721 0.1789 0.9964 0.9902 0.40 
F7 0.7938 0.5678 0.9215 0.9989 0.65 
F8 0.765 0.6615 0.9029 0.9991 0.63 
F9 0.7243 0.3957 0.8808 0.9997 0.56 
F10 0.7221 0.4745 0.8792 0.9987 0.57 
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The mechanism of drug release through matrices containing water soluble and swellable 
polymers in combination with lipophilic binders is a more complex process. Formulations 
containing HPC in combination with stearic acid (F7-F10) demonstrated a good fit to the 
Korsmeyer–Peppas equation, indicating combined effects of diffusion and erosion mechanisms 
for drug release. Moreover, the release exponent n was within the range of 0.50-0.89, indicating 
a non-Fickian diffusion mechanism and that drug release was governed by both diffusion and 
matrix erosion. Thus, drug release was controlled by more than one process in the case of the 
HPC-SA matrices. 
Conclusion 
It can be concluded from this study that the continuous melt granulation technique within a twin-
screw extruder is a viable method to develop a sustained release tablet of OND. The granules 
prepared with the melt granulation binder (stearic acid) exhibited good flowability as well as 
good compressibility with a fewer amount of fines. Stearic acid in combination with EC (F3) 
demonstrated prolonged release of OND for 24 h with 90% drug release, whereas stearic acid in 
combination with HPC (F7) showed 100% drug release over a period of 9 h. The incorporation 
of fumaric acid in the formulation led to the improvement of OND release from both EC-SA and 
HPC-SA systems. Thus, this work formulated a sustained release OND matrix tablet that was not 
influenced by pH in dissolution testing. In conclusion, the novel aspect of the current study is its 
demonstration of the feasibility to continuously manufacture ready-to-compress melt granules of 
OND by a twin-screw extruder that can be processed into tablets to provide pH-dependent/pH-
independent sustained release of the drug. 
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CHAPTER IV 
NOVEL DRY-GRANULATION PROCESS FOR CONTROLLED RELEASE 
FORMULATIONS OF ONDANSETRON HYDROCHLORIDE DIHYDRATE USING 
TWIN SCREW EXTRUDER 
4.1. Abstract 
The aim of this study was to apply a quality by design (QbD) approach based on design of 
experiments as a risk-based proactive approach to achieve predictable critical quality attributes 
(CQAs) to develop a dry-granulation process for controlled release formulation of Ondansetron 
sustained release tablets by twin-screw extruder. Optimization of formulation and process 
parameters reduces the variability and thus results in the quality improvement, risk reduction and 
productivity enhancement. Preliminary studies were conducted to select screw design, ratio of 
polymers and barrel temperature to achieve dry granulation via twin-screw extruder. Further, the 
effect of screw speed, feed rate and amount of fumaric acid on the particle size and flow 
properties of the granules and time required for complete and controlled release of the drug from 
the dosage was optimized by 23 factorial design. Based on the design of experiment (DOE) 
results, a formulation comprising of 2.5% (w/w) fumaric acid extruded at high screw speed (100 
rpm) and low feed rate (1%) was found to fulfill requisites of an optimum formulation. The 
optimized formulation Z8 showed High percentage of medium size granules (89%), low angle of 
repose (25), and the formulation showed sustained release of OND over the period of 15.5 h with 
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100% drug release. This study introduces the novel dry granulation process for the development 
of OND controlled release formulation via twin-screw extruder as well as highlights the level of 
understanding that can be accomplished through a well-designed study based on the approach of 
QbD. 
 4.2. Introduction    
Granulation is a process in which the small particles are made to cohere into larger, multi-
particle masses, so called granules i.e. a process of small particle enlargement by agglomeration 
phenomena. This process is routinely utilized in the pharmaceutical industries in order to reduce 
dust of the small particles thus preventing the potential health and environmental hazard, to 
prevent segregation, granules are easy to handle and transport, and also they are free flowing 
therefore useful for dosage filling (capsules) and compression process (tablets) [73-75]. 
Granulation process can be divided into two types: wet and dry granulation. Wet granulation 
process which utilizes some form of solvent to bind the small particles together and dry 
granulation process is performed without adding any solvent. The methods utilized for wet 
granulation are either low-shear mixing, high-shear mixing, extrusion-spheronization or fluid-
bed processing, whereas dry granulation process involves either slugging or roller compression 
[73]. The obtained compacts in the dry granulation process is known as briquettes, flakes or 
ribbons and in order to obtain the desired granules, the compaction process is further followed by 
a milling step. Apart from these granulation methods, twin-screw extruder has now been 
extensively utilized for granulation process.  
Twin-screw extrusion is a continuous solvent-free process, in which the physical mixture is 
introduced into the extruder through the feeder and the extrudate is collected through the die 
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block under the controlled feeding rate, temperature, mixing (kneading with the help of different 
screw configuration), and pressure. Whereas, in case of granulation process in order to collect 
the granules continuously, the twin-screw extruder is used without the die block in order to 
prevent the immoderate densification of material inside the barrel. As per the literature, till now 
only wet and melt granulations were prepared by twin-screw extruder. The continuous 
production of dry granules via twin-screw extruder has not previously been demonstrated. 
Therefore, the objective of this study was to develop a continuous twin-screw dry granulation 
process to prepare dry granules using a model drug ondansetron (OND) for formulating 
sustained release tablets. OND, a carbazole derivative, is a competitive and selective serotonin 
(5-HT3) receptor antagonist recommended for preventing nausea and emesis in the patients 
undergoing cancer chemotherapy and radiation therapy, and it is also used to prevent post-
operative nausea and episodes of emesis. OND is commercially available in both oral and 
injectable forms. OND has a relatively short terminal elimination half-life of approximately 3-5 h 
following the oral administration and therefore, sustained release formulation is needed for this 
drug.  
The final goal of this study is to apply QbD approach to the optimization of OND sustained 
release formulation prepared via twin-screw dry granulation process. The important part of this 
approach is to understand how formulation and process parameters affect the product 
performance and following optimization parameters with respect to final stipulation. 
4.3. Materials and Methods: 
4.3.1. Materials 
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Ondansetron HCl dihydrate was purchased from Chemscene LLC (New Jersey, USA). 
Hydroxypropyl cellulose (Klucel EF) was generously gifted by Ashland Specialty Ingredients 
(Wilmington, DE). Ethyl cellulose (Ethocel Standard 10) was kindly gifted by Dow chemical 
company. Fumaric acid and Magnesium stearate was purchased from Spectrum Laboratory 
Products Inc. (Gardena, CA). All the other reagents used in this study were of the analytical 
grade. 
4.3.2. Methods: 
4.3.2.1. Drug-excipient interaction studies 
In order to study the interaction of OND with the polymers and other excipients used in this 
study, physical mixture was prepared in 1:1 ratio by mixing the OND with each of the 
formulation excipients. Differential scanning calorimetry (Diamond DSC, Perkin Elmer Life and 
Analytical Sciences, 710 Bridgeport Ave., Connecticut, USA) equipped with Pyris manager 
software (Shelton, CT, USA) and Fourier transform infrared spectroscopy (FTIR, Agilent 
Technologies Cary 660, Santa Clara, CA) was utilized to study the compatibility of OND with 
other excipients. In brief for DSC study, samples were prepared by hermetically sealing 
approximately 3-5 mg of pure API and physical mixture in an aluminum pans. These samples 
were then heated over a temperature range of 40-250 oC at a linear heating rate of 10 oC/min 
under an inert nitrogen atmosphere. Whereas mid- infrared spectra in the range of 4000-650 cm-1 
were collected on FTIR bench equipped with an MIRacle ATR (Pike Technologies, Madison, 
WI), which was fitted with a single bounce diamond coated ZnSe internal reflection element. 
4.3.2.2. Preliminary screening for the selection of formulation variables and process 
variables 
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Preliminary studies were conducted to determine the process parameters, screw configuration 
and barrel temperature as well as formulation parameters such as ratio of polymers, type and 
amount of acidifier and lubricant required for the successful dry granulation process. The effect 
of all these parameters on the quality of granules was studied. As well as the API form 
(crystalline/amorphous) present in the granules were determined.  
Table 4.1: Formulation composition 
Formulations Ondansetron 
(%) 
EC 
(Ethocel® 
10P) (%) 
HPC EF 
(%) 
Fumaric 
acid (%) 
Mg.S. (%) 
Formulation A 20% 36.25% 36.25% 7.5% 0.2% 
intragranule 
plus 0.3% 
extragranule 
Formulation B 20% 37.5% 37.5% 5% 0.2% 
intragranule 
plus 0.3% 
extragranule 
Formulation C 20% 38.75% 38.75% 2.5% 0.2% 
intragranule 
plus 0.3% 
extragranule 
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Table 4.2: Barrel Temperature Setting 
Barrel Temperature 
Feed 
Zone 
Zone 2 Zone 3 Zone 4 Zone 5 Zone 6 Zone 7 Zone 8 Die 
°C 
N/A 70 70 80 90 80 70 70 40 
 
4.3.2.3. Twin-screw extrusion process for the dry granulation 
Formulation composition and the processing parameters are as shown in the Table 4.1 and 4.2, 
respectively. Briefly, ondansetron HCl dihydrate and other inactive ingredients were passed 
through US mesh # 35 (500 µM) in order to remove any aggregates that may have formed. 
Organic acid (Fumaric acid) was added in the formulation composition in order to solve the pH-
dependent solubility of the OND. Magnesium stearate was also added in the formulation 
composition as a lubricant to prevent squeaking noises generated by the extruder while extruding 
these formulations. Further, the physical mixture (OND (20% w/w) and other inactive 
ingredients) was mixed using a V-shell blender (GlobePharma, MaxiblendTM New Brunswick, 
NJ) at 25 rpm for 20 min. Dry granulation process was performed without an extrusion die block 
in a fully intermeshing co-rotating twin-screw extruder (11 mm Process 11TM Thermo Fisher 
Scientific) with modified screw configuration design (Fig 4.1). The prepared physical mixture 
was fed to the extruder with the help of volumetric feeder through the first zone (no heating). 
Temperature for all barrel zones were selected based upon the preliminary study optimization 
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and was below the melting point of OND (189 oC) (Table 4.2). Also the powder feed rate (g/min) 
and the screw speed (rpm) were set at two levels, low and high and were selected based on the 
preliminary study and varied according to the process parameter. As soon as the steady state was 
reached the granules were collected at the end of discharge element of the extruder (without the 
die block). The collected granules were stored in sealed aluminum pockets for further analysis. 
 
Fig 4.1: Screw design 
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Table 4.3: Quality target product profile 
QTPP Element Target Justification 
Dosage form Tablet 
Pharmaceutical equivalence 
requirement: same dosage form 
Route of administration Oral 
Pharmaceutical equivalence 
requirement: 
same route of administration 
Dosage strength 30 mg  
Pharmacokinetics 
In-vitro dissolution – 12-15hrs 
80% release 
 
Stability 
At least 6 months 40C/75RH 
accelerated stability 
 
Drug Product quality 
attributes 
Physical Attributes Tablets (size, color, shape) 
Identification 
Positive identification for 
ondansetron HCl dihydrate 
Assay 
90.0-110.0 (Compendial 
requirement) 
Content Uniformity AV < 15.0 (USP<905>) 
Degradation Products Monitor and report (CQA) 
DSC Monitor and report (CQA) 
TGA Monitor and report (CQA) 
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XRPD Monitor and report (CQA) 
NIR Monitor and report (CQA) 
Residual Solvents 
Will not be monitored for this 
study 
Drug Release ER 
Microbial Limits 
Will not be monitored for this 
study 
Water Content 
Will not be monitored for this 
study 
Container Closure System NA  
Administration/concurrence 
with labeling 
NA 
 
Alternate methods of 
administration 
NA 
 
 
4.3.2.4. QbD approach for the development of dry granules via twin-screw extruder 
QbD study involves several key elements in it such as quality target product profile, 
determination of critical quality attributes (CQAs), and relationship between formulation/process 
parameters with CQAs and based on it, determines the risk assessment and development of 
design space for the optimization of formulation. Quality target product profile were set for the 
desired formulation and given in Table 3. Primary determinants of OND sustained release 
formulation prepared by twin-screw dry granulation process were selected as CQAs for the 
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formulation and process optimization. The CQAs and their acceptance limits are listed in table 
4.4.  
Table 4.4: Quantification of CQAs 
CQAs Desired target value 
Particle size 1.4 mm – 500 μm 
Angle of Repose 25-31 
Dissolution time (100% drug release) 12-16 h 
Table 4.5: Initial risk assessment 
 
 
Drug Product CQAs 
Process steps 
Twin Screw 
extrusion 
Milling Compression 
Particle Size Low Low High 
Assay High Low Low 
Content Uniformity High Low Low 
Drug Release High High High 
Drug release –alcohol-
induced dose dumping 
High High High 
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Initial risk assessment was determined to identify potentially high risk formulation and process 
variables and to determine which studies were necessary to achieve product and process 
understanding in order to develop a control strategy (Table 4.5).                                              
 Table 4.6: 23 Full Factorial Design (with 2 center points) 
 
 
 
 
 
 
 
 
 
 
4.3.2.5. Experimental design 
A full 3 factor, 2 level (23) factorial design was used to optimize the process and formulation 
parameters (Table 4.6 and 4.7). A total 10 trial formulations were proposed by the 23 factorial 
designs for three independent variables (factors) namely, feed rate, screw speed and amount of 
fumaric acid, which were varied at two levels (low and high). Particle size distribution (PSD), 
Factor 
(independent 
variables) 
Level-1 Level+1 Responses 
(dependent variables) 
Screw Speed 
(RPM) 
25 100 1. Particle size 
2. % Dissolution  
3. Flow properties Feed Rate 
(%) 
1 3 
Fumaric acid 
(%) 
2.5 7.5 
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dissolution time and flow properties (angle of repose) were selected as the response variables. 
The linear equation of the model is as follows: 
Y = b0 + b1X1 + b2X2 + b3X3 + b4X4 + b5X5 + ·· ·+ bnXn…………….Eq. 1 
where Y is the dependent variable, b0 is the arithmetic mean response, b1, b2, b3, b4 and b5 are 
the estimated co-efficient for the factor X1, X2 and X3. The statistical analysis of the factorial 
design formulations was performed using Design-Expert® (Version 9.0.5, Stat-Ease Inc., 
Minneapolis, MN). 
Table 4.7: Design of experiments 
Screw Speed 
(RPM) 
Batch 
Feed Rate 
(g/hr) 
Fumaric Acid 
(%) 
Torque (%) 
Specific Energy 
(kw hour /kg) 
25 
Z1 40 7.5 15.83 0.009 
Z2 40 2.5 16.66 0.01 
Z3 120 2.5 33.33 0.01 
Z4 120 7.5 41.66 0.01 
62 
Z5 80 5 28.33 0.02 
Z6 80 5 30 0.02 
100 
Z7 120 2.5 35 0.03 
Z8 40 2.5 20 0.04 
Z9 120 7.5 35.83 0.03 
Z10 40 7.5 20 0.04 
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4.3.2.6. Physicochemical properties of granules 
4.3.2.6.1. Particle size distribution 
Sieve analysis method was used to determine the particle size distribution. Two USA standard 
test sieve, # 35 (500 µm) and # 14 (1.4 mm) were used and the amount of granules retained on 
each sieve were weighed. Three fractions were collected, first the granules size of more than 1.4 
mm retained at the topmost sieve (# 14), second the granules size of between 1.4 mm – 500 µm 
retained at the second sieve (# 35), finally fines were collected at the bottom having granules size 
less than 500 µm. Percentile weight distribution was determined for all of the three fractions.    
4.3.2.6.2. Flow Properties 
The bulk volume (Vo) of 5 g of granules was measured in 10 ml of graduated glass cylinder. The 
bulk density (ρb) was calculated by the following equation:  
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (𝜌𝑏) =
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑔𝑟𝑎𝑛𝑢𝑙𝑒𝑠 𝑤𝑒𝑖𝑔ℎ𝑒𝑑 (5 𝑔)
𝑏𝑢𝑙𝑘 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑉𝑜)
… … … … 𝐸𝑞. 2 
The graduated glass cylinder was tapped manually 100 times until no further reduction in the 
volume of the granules was observed. Tapped density (ρt) was calculated by using the volume of 
the granules after tapping 100 times (V100) by the following equation:   
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (𝜌𝑡) =  
𝑎𝑚𝑜𝑢𝑛𝑡  𝑜𝑓 𝑔𝑟𝑎𝑛𝑢𝑙𝑒𝑠 𝑤𝑒𝑖𝑔ℎ𝑒𝑑 (5 𝑔)
𝑡𝑎𝑝𝑝𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑉100)
… … … … Eq. 3 
   
Carr’s (compressibility) index (CI) and Hauser’s ratio (HR) was calculated by the following 
equations: 
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𝐶𝐼 =
(𝜌𝑡 − 𝜌𝑏)
𝜌𝑡
 × 100 … … … … 𝐸𝑞. 4 
      
𝐻𝑅 =  
𝜌𝑡
𝜌𝑏
… … … . 𝐸𝑞. 5 
Angle of repose was determined by funnel method. The height of the funnel above the horizontal 
plane surface, on which the wax paper was placed, was adjusted in such a way that the tip of the 
formed cone of the granules just touched the tip of the funnel. The accurately weighed granules 
were freely poured through the funnel on the wax paper. The diameter and the height of the cone 
were measured and the angle of repose (θ) was calculated by the following equation:     
𝑇𝑎𝑛 (𝜃) =  
ℎ
𝑟
… … … 𝐸𝑞. 6 
Where, ‘h’ and ‘r’ are the height and radius of the formed cone, respectively.   
4.3.2.6.3. True Density and Surface Area 
The true density of the granules was measured (n=3) with the help of helium pycnometer 
(AccuPyc II 1340 Pycnometer, Micromeritics, USA). The surface area of the granules was 
determined (n=3) using Gemini VII 2390 (Micromeritisc, USA). 
4.3.2.7. Tablet Compression 
The obtained granules were mixed with 0.3% magnesium stearate just prior to manual direct 
compression on a single punch tablet press (MCTMI, GlobePharma Inc., New Brunswick, NJ), 
by using an 8 mm flat round punch at a compression force of 140 kg/cm. 
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4.3.2.8. Tablet Evaluation 
The prepared compressed tablets were evaluated for hardness, thickness, friability and drug 
content uniformity. For hardness test, ten tablets were randomly selected and were tested with 
Schleuniger-hardness tester. The thickness of the tablets (n=10, randomly selected) were 
measured by digital Vernier caliper (Montata). The tablet friability was determined using a dual 
scooping projection Vander Kamp friabilator (Vankel Industries Inc., Chatham, NJ) at speed of 
25 rpm for 4 min. The percentage weight loss of tablets (weighing 6.5 g) was expressed as the 
tablet friability. For drug content uniformity, tablets (n=10, randomly selected) were accurately 
weighed and average weight was calculated. Briefly, they were grounded with the help of mortar 
and pestle, and powder equivalent to 10 mg of OND was accurately weighed and dissolved in 0.1 
N HCl. The absorbance was measured at λmax 305 nm using UV-VIS Spectrophotometer and 
the percentage drug content was calculated using calibration curve of OND. 
4.3.2.9. In-vitro drug release 
In-vitro drug release from the compressed tablets was measured using USP dissolution apparatus 
type-II (Hanson SR8 Plus), set at a paddle speed of 50 rpm and equipped with UV-Vis probes 
(Rainbow dissolution monitor, PION). The UV spectra were collected at λmax 305 nm every 2 
min for first 2 h and then for every 25 min until 24 h. For the first 2 h the dissolution media 
consisted of 700 ml of 0.1 N HCl (pH 1.2) with 1% sodium laurly sulfate (SLS), after that 200 
ml of 0.2 M tribasic sodium phosphate (pH 12.5) with 1% SLS (maintained at 37 ± 0.5 oC) was 
added to achieve final pH of 6.8 for 24 h, in order to simulate the tablet transit from the stomach 
(pH 1.2) to the intestine (pH 6.8). In-vitro drug release study was performed in triplicate and the 
mean % drug release was plotted against time (h).  
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4.3.2.9.1. Computation of release kinetics of 30 mg ondansetron HCl dihydrate matrix 
tablet 
In order to study the mechanism of drug release kinetics from the optimized formulation of 30 
mg ondansetron HCl dehydrate matrix tablet, the in-vitro drug release dissolution data was 
evaluated kinetically by the following equations: 
𝑍𝑒𝑟𝑜 − 𝑜𝑟𝑑𝑒𝑟 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛: 𝑄𝑡 =  𝑄0 +  𝐾0𝑡 … … … 𝐸𝑞. 7 
𝐹𝑖𝑟𝑠𝑡 − 𝑜𝑟𝑑𝑒𝑟 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛: 𝑙𝑜𝑔 𝑄𝑡 =  𝑙𝑜𝑔 𝑄0 + 
𝐾1𝑡
2.303
… … … 𝐸𝑞. 8 
𝐻𝑖𝑔𝑢𝑐ℎ𝑖 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛: 𝑄𝑡 =  𝐾𝐻√𝑡 … … … 𝐸𝑞. 9 
𝐾𝑜𝑟𝑠𝑚𝑒𝑦𝑒𝑟 − 𝑃𝑒𝑝𝑝𝑎𝑠 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛: 
𝑄𝑡
𝑄∞
=  𝐾𝑘𝑝𝑡
𝑛 … … … . 𝐸𝑞. 10 
where, Qt is the amount of drug released in time t, Q0 is the initial amount of the drug in the 
solution (most of the time Q0 = 0), Q ͚ is the amount of drug released after infinite time, K0 is the 
zero order release rate constant, K1 is the first order release rate constant, KH is the Higuchi 
diffusion rate constant, Kkp is the kinetic release constant incorporating structural and 
geometrical characteristics of the tablets and ‘n’ is the diffusion release exponent indicating the 
drug release mechanism. The mechanism of drug release is dependent on the value of ‘n’. 
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4.4. Result and discussion 
4.4.1. Compatibility testing (Drug-excipient interaction): 
The selected DSC curve of OND and physical mixture is shown in the Fig 2. The DSC curves 
represent a well-recognized melting point endothermic peak of pure drug (OND) in the range of 
185.2-188.58 oC. DSC results also indicated that OND is compatible with polymers used in this 
study as there was no change in the glass transition temperature and melting endotherms of other 
excipients used in the formulation. This was further confirmed by FTIR, as there was no change 
in the IR of the OND when mixed with other excipients, thus indicating the absence of drug-
excipient interaction. 
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Table 4. 8: DOE Results 
Batch 
>1.4 mm 
% (14 
Mesh) 
Medium  
% 
< 500 
microm 
% 
(35mesh) 
Hausner’s 
Ratio 
Carr’s 
Index 
Angle of 
Repose 
Dissolution 
Time for 
100% Drug 
Release (h) 
Z1 40.77381 53.21621 6.009985 1.09 8.69 34 6.5 
Z2 26.04511 65.20301 8.75188 1.22 18.18 36 6.5 
Z3 70.39839 24.6483 4.953304 1.13 11.53 33 7.5 
Z4 81.45596 14.66561 3.878434 1.08 8 43 7.5 
Z5 46.61275 48.99556 4.391686 1.13 11.53 30 9.5 
Z6 37.40889 57.97194 4.619169 1.13 11.53 31 10.5 
Z7 37.91596 57.76051 4.323537 1.13 11.53 36 9.5 
Z8 5.575453 89.6525 4.772045 1 0 25 15.5 
Z9 46.101 49.33976 4.559243 1.22 18.51 31 12.5 
Z10 28.5657 68.91675 2.517553 1.04 4 27 15.5 
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4.4.2. Preliminary study 
4.4.2.1. Screw configuration 
Different screw configurations were tried to produce dry granules by using twin-screw extruder. 
Conveying screw configuration without any mixing zone resulted in the generation of 20% 
granules and more than 80% materials were remained as un-granulated fine powders, even under 
high temperature processing. Screw configuration with increase in mixing zone resulted in the 
generation of more granules and less fines. However, there were lots of big particles formed 
when the two and three mixing zones were utilized in the screw configuration. Also, screw 
configurations more than one kneading zone results in the formation of rubbery texture granules 
which were hard to break while passing through sieve. One kneading zone yielded good quality 
granules and the particle size distribution was good with around 89% granules of the desired 
particle size range (500 μm – 1.4 mm) with few big particles as shown in Table 8. Therefore, for 
further investigation of the dry granulation process, one kneading zone screw configuration was 
fixed.  
4.4.2.2. Barrel temperature 
 Different barrel temperatures were tried to optimize the barrel temperature in order to produce 
dry granules of OND. High temperature resulted in the melting of HPC polymer and formation 
of big agglomerated granules. Due to the melting of HPC polymer the big granules formed were 
rubbery in texture and were difficult to break easily. Based on the preliminary study results, 
barrel temperature of around 70-90 oC showed promising results and therefore this barrel 
temperature was kept constant for the further experiments. Digital images are shown in Fig.3 for 
the granules prepared with different screw configurations and at different temperatures. 
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4.4.2.3. Ratio of polymer  
1:1 and 3:1 ratio of EC and HPC were studied to optimize the ratio of polymers. Among these 
two, 1:1 ratio showed the larger percentage of medium size granules. From these preliminary 
study results, screw configuration having one kneading zone, 1:1 ratio of EC and HPC and barrel 
temperature (70-90 oC) was selected as constant parameters for further optimization of other 
process and formulation parameters. 
4.4.2.4. Addition of acidifier:  
It was observed that the formulations without organic acid were unable to release the drug in 
intestinal pH media due to its weakly basic nature. Presence of organic acid in the tablet creates a 
constant acidic micro-environment inside the tablets. Therefore, irrespective of the pH of the 
surrounding dissolution medium, organic acid assisted in the solubilization and release of OND 
in high pH dissolution medium corresponding to the intestinal pH. Among the three organic 
acids (citric acid, adipic acid and fumaric acid ), fumaric acid showed promising results as it was 
able to release 100% drug at intestinal pH.  
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Fig 4.2: Digital images showing pre-screening effects of screw configuration and barrel 
temperature on granules size 
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4.4.2.5. Addition of Lubricant:  
As this is the dry granulation process all the material remain in a solid state throughout the 
process and therefore, lubrication step is essential in order to reduce the friction between the 
surfaces of manufacturing equipment that is in this case twin-screw extruder and that of organic 
solids as well as to ensure the continuation of an operation (appropriate torque values). 
Magnesium stearate was used in the formulation composition as the lubricant. Although 
magnesium stearate act as a lubricant and ease the dry granulation extrusion process, too much 
magnesium stearate will have adverse effects on tablet hardness and dissolution because it is 
non-soluble in water. Therefore, generally the recommended amount to be used in the 
formulation should be less than 1%. To avoid the adverse effects 0.2% of magnesium stearate 
was used to prepare the dry granules via twin-screw extruder. 
4.4.3. Design of experiments 
23 factorial design was implemented to evaluate the main effects and interaction effects of 
independent variables screw speed, feed rate and amount of fumaric acid on the dependent 
variables to obtain the desired granule size, flow properties for the granules prepared by twin-
screw dry granulation process and sustained drug release profile of the drug from tablets 
containing dry granules.  
4.4.4. Characterization of Granules 
Yields of granulation process were found to be high (97-99%). It was observed that as the 
process was dry granulation no excipients as well as API was melted at the set process 
parameters and therefore, no loss of material was seen in the process. After experiment get over 
when the barrel top was opened, no sticking of material was observed inside the barrel walls or 
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screws itself. The granules of different formulations were evaluated for crystallinity, particle 
size, flow properties, true density and surface porosity. 
4.4.4.1. Crystallinity 
 DSC was conducted for pure drug and dry granules prepared by twin-screw extruder. DSC curve 
of pure OND shows a melting endothermic peak at 189 oC and for all formulation Z1-Z10, an 
endothermic peak was observed in the range of 185 - 191 oC. From DSC data it can be inferred 
that at the employed twin-screw extruder process parameters as well as formulation parameters 
for all the formulations, crystalline structure of OND was not lost. 
4.4.4.2. Particle size distribution: 
Granule particle size distribution results for all the formulation have been shown in Table 8. 
Three granule size factions were collected that is big granules (> 1.4mm), Medium size granules 
(fraction between 1.4 mm- 500 μm) and un-granulated fines (< 500μm). For the tableting 
purpose medium size granules, fraction between 1.4 mm- 500 μm is the important fraction along 
with the requirement of 10-15% fines in order to get good compressibility. And it is desirable to 
get maximum percent of granules of medium size. Therefore, particle size between 1.4 mm – 500 
μm was selected as the one of the dependent variable (response) in 23 factorial design. 
The following polynomial equation was generated for granule size prepared by twin-screw dry 
granulation process: 
Particle size = +53.03 + 13.49 *A -16.32 *B -6.39 *C + 3.45 *AB + 1.79 *BC …………Eq. 11 
Where, A, B and C are the screw speed, feed rate and amount of fumaric acid respectively. A 
positive or negative sign of the polynomial terms indicates increase or decrease effect on 
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response by different level combination of independent variables. ANOVA of the equation 
suggested the Model F-value of 40.23 implies the model is significant. The “Lack of Fit F-value” 
of 0.24 implies the Lack of Fit is not significant (p > 0.0001). The model was statistically 
significant for the response particle size with “R-squared” of 0.9852, "Pred R-Squared" of 
0.7971 and "Adj R-Squared" of 0.9336 which are close to unity. The "Pred R-Squared" is in 
reasonable agreement with the "Adj R-Squared". The adequacy/precision ratio was 24.026 
indicating signal adequacy. All three independent factors feed rate, screw speed and amount of 
fumaric acid were found to have significant effect on the particle size of granules. The most 
significant factor among these three was feed rate. Highest percentage of medium size granules 
were obtained at lower feed rate (1%). Feed rate showed negative coefficient for response 
particle size indicating increase in feed rate from 1 to 3 results in the decrease in the percentage 
of medium size granules. In order to achieve higher percentage of medium size granules it is 
preferred to keep low feed rate this may be attributed by the amount of material present inside 
the barrel affects the agglomeration step and with high feed rate high amount of material forcing 
to pass through the barrel resulting in more dense and big particles.  
Screw speed was found to be another factor with the significant influence on particle size. 
Positive coefficient for the factor screw speed indicates that it has positive effect on the particle 
size. Increasing screw speed from 25 to 100 rpm resulted in the increase in the percentage of 
medium size granules at all three levels of amount of fumaric acid. Increase in screw speed 
results in the decrease in the residence time as well as high shear generation which might be the 
reason for formation of granules but with the more percentage of medium size granules. 
The third independent variable, amount of fumaric acid showed negative coefficient indicating 
high fumaric acid content in the formulation gives low percentage of medium size granules. This 
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may be due to the differences in the particle size of fumaric acid and other formulation 
composition utilized in this process. Hence it may be concluded that to maximize the percentage 
of medium size granules, low feed rate, high screw speed and low amounts of fumaric acid 
should be used to get the optimum response. The Eq. 11 is presented in the form of a contour 
plots and response surface graphs to visualize the effect of all changing independent variables on 
granule size (Fig. 4.3). 
 
 
Fig 4.3: Response particle size Contour plot and Response surface graph 
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4.4.4.3. Flow properties:  
Granule flow properties are critical to mixing, die filling and tableting, which may significantly 
affect dosage uniformity, content and tablet mechanical characteristics. Granule flowability have 
been assessed by measuring Hausner’s ratio, Carr’s index and Angle of repose for all the 
formulations and results are summarized in Table 8. A Hausner’s ratio less than 1.25 is 
considered an indication of good flowability. All the formulations Z1-Z10 showed Hausner’s 
ratio value less than 1.25. A Carr’s index below 15 is considered an indication of good 
flowability (reference). All the formulations showed Carr’s index value less than 15 except 
formulation Z2 and Z9. The angle of repose in a range of 25 to 30 indicates excellent flow 
properties (USP reference). Formulations Z5, Z8 and Z10 showed excellent flow (angle of 
repose < 30) and other formulations showed angle of repose more than 30. 
Based on 23 factorial design, screw speed and feed rate was found to be the significant factors 
affecting flowability of granules. A polynomial regression equation to describe the response 
variation to the three variables within the design space was generated. The reduced equation after 
correction for insignificant terms (in coded units) was: 
Angle of Repose = +32.60 - 3.37 *A + 2.63 *B + 1.12 *AB – 1.38 *AC -2.37 *ABC……Eq. 12 
Model F-value of 19.26 for the adjusted model implies the model is significant. Lack of fit F-
value of 6.25 indicates that the lack of fit is not significant. The adequacy/precision ratio was 
10.258 indicating signal adequacy. Screw speed showed the most significant effect on angle of 
repose of granules. Negative coefficient for screw speed factor indicates the increase in screw 
speed results in the decrease in the angle of repose that means improving flowability of granules 
with increase in screw speed. Whereas, feed rate showed positive coefficient which implies 
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increase in feed rate will result in increase in angle of repose that is poor flowability of granules. 
These results are well correlated with the particle size of the granules. High screw speed and low 
feed rate gives the higher percentage of medium size granules that is improving the flowability 
of granules and therefore lowering the angle of repose. The effect of selected independent 
variables on angle of repose of granules is represented in contour plots and response surface 
graphs (Fig. 4.4). 
 
 
Fig 4.4: Response Angle of Repose Contour plot and Response surface graph 
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Table 4.9: True density and surface area of twin-screw dry granules 
Formulation True density Surface area (m2/g) 
Z1 1.2419±0.0013 0.2747±0.0021 
Z2 1.2421±0.0024 0.2015±0.0046 
Z3 1.2490±0.0014 0.2804±0.0023 
Z4 1.2643±0.0011 0.1717±0.0023 
Z5 1.2801±0.0012 0.3347±0.0080 
Z6 1.2786±0.0013 0.1278±0.0034 
Z7 1.2227±0.0017 0.3579±0.0093 
Z8 1.2246±0.0055 0.3239±0.0079 
Z9 1.2163±0.0014 0.3904±0.0094 
Z10 1.2185±0.0008 0.2565±0.0061 
 
4.4.4.4. True density and Surface Area:  
The true density and surface area of granules for all the formulations has been reported for the 
granule size between 1.4 mm – 500 μm in Table 4.9. 
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4.4.5. Characterization of tablets: 
4.4.5.1. Physicochemical properties  
All the formulations showed uniform weight, thickness and hardness. The average percentage 
deviation of 20 tablets of each formula was less than ± 5% and hence all formulations passed the 
test for uniformity of weight as per USP official requirements. Good uniformity content was 
found among three different batches of tablets.  
 
Fig 4.5: Drug Release Profile 
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4.4.6. In-vitro release study 
The in-vitro release of the drug from all of the formulations has been investigated in gastric fluid 
(pH 1.2) during first 2 h and then in intestinal fluid (pH 6.8) for the next 22 h. For all the 
formulations, 100% drug release was achieved but at different time points (Fig. 4.5). The 
equation derived by best fit mathematical model for dissolution time response with independent 
variable was:  
Dissolution time = +10.10 + 3.13 *A -0.88 *B + 0.38 *C – 1.38 *AB + 0.38 *BC……….Eq. 13 
ANOVA analysis of the model equation suggests the F value 26.49 (p < 0.0001) indicating the 
significance of model. The adequacy/precision ratio was 13.950 indicating signal adequacy. It 
was observed that screw speed is the dominant factor affecting drug release profile. Positive 
coefficient of screw speed indicates the high screw speed requires more time to release 100% 
drug from the dosage resulting in slower drug release as compared to medium and low screw 
speed. This might be due to the increase in screw speed results in high shear generation which 
results in more binding between drug and polymer resulting in slower release of drug from 
granules. No differences in dissolution profile were observed at low screw speed. Center point 
formulations that are Z5 and Z6 showed intermediate dissolution profiles as compared to low and 
high screw speed batches.   
A negative interaction was also observed for AB which has significant effect on dissolution time. 
Increasing the screw speed expectedly increased the interaction between drug and polymer 
resulting in the slower drug release from the dosage. At low feed rate the amount inside the 
material is less and therefore high screw speed at low feed rate resulting in more shear generation 
on the material.  
 98 
 
The Eq. 13 is presented in the form of a contour plots and response surface graphs to visualize 
the effect of all changing independent variables on dissolution time (Fig. 4.6). 
 
 
Fig 4.6: Response Dissolution time Contour plot and Response surface graph 
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Table 4.10: Drug release kinetics 
Formulation Zero Order First order Higuchi Krosmeyer peppas 
 R2 R2 R2 R2 N 
Z1 0.9509 0.9444 0.991 0.9995 0.75 
Z2 0.9481 0.878 0.9878 0.999 0.72 
Z3 0.9342 0.9708 0.9818 0.9993 0.69 
Z4 0.9139 0.9808 0.979 0.9983 0.70 
Z5 0.9168 0.8568 0.9822 0.9993 0.63 
Z6 0.894 0.9066 0.9777 0.9973 0.62 
Z7 0.947 0.8014 0.9843 0.9985 0.58 
Z8 0.919 0.8323 0.9926 0.9982 0.59 
Z9 0.9151 0.9754 0.9761 0.9986 0.63 
Z10 0.9433 0.9011 0.9988 0.9997 0.62 
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4.4.7. Kinetic modelling of cumulative drug release data  
To understand the drug release mechanism from all the 10 formulations Z1-Z10, the in-vitro 
release data were analyzed according to kinetic equations such as zero-order, first-order, Higuchi 
and Korsmeyer-Peppas. The release rate kinetic data for all the models can be seen in Table 4.10. 
As shown in Table 4.10, kinetic modeling of the release data for all the formulations were best 
fitted to Korsmeyer-peppas model. The diffusion coefficient value (n) for all the formulations are 
within the ranges of 0.59 - 0.72, indicating a non-Fickian diffusion mechanism and that drug 
release was governed by both diffusion and matrix erosion.  
 
Fig 4.7: Numerical and graphical optimization: Desirability plot and overlay plot 
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4.4.8. Numerical and graphical optimization  
The optimized formulation was selected based on the set criteria of the desired CQA’s in the 
formulation.  The percentage of medium size granules and dissolution time required for attaining 
the complete and controlled drug release were set at maximum, whereas angle of repose was set 
at minimum level. Desirability plot was constructed to understand the relationship between 
independent variables and response values (Fig. 4.7). In order to achieve the goal of best 
formulation, granules should possess good flow properties (lower angle of repose, 25-31), higher 
percentage of medium size granules (70-90%) and more time should be required for dissolution 
of dosage (12-16 h). The calculated desirability value for the formulation Z8 is 0.880 which 
indicated suitability of the designed factorial model. Along with desirability plot, graphical 
optimization overlay plot for the set response variables is also analyzed (Fig 4.7). It was 
observed that the optimized formulations with the desired set goals can be achieved at high 
screw speed (100 RPM), low feed rate (1% or 80 g/hr) and low amount of fumaric acid (2.5%) in 
the formulation.  
4.5. Conclusion 
To the best of our knowledge this is the first study in which twin-screw extruder is utilized to 
develop a novel continuous dry granulation process. QbD approach was successfully used in the 
preparation of OND sustained release formulation via twin-screw dry granulation process. Free 
flowing granules with angle of repose 25, medium particle size percentage around 89% and the 
drug release from the tablet was achieved 100% over the period of 15.5 h. Therefore, the 
optimized formulation was able to achieve the set target goals of CQAs. The information 
obtained from this study introduces third method of dry granulation process via twin-screw 
extruder which can be an adequate method in terms of its overall simplicity as compared to the 
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currently available methods for dry granulation as well as the feasibility to control and optimize 
crucial factors more easily, such as particle size. In conclusion, the novel aspect of the current 
study is its demonstration of the feasibility to continuously manufacture ready-to-compress dry 
granules of OND by a twin-screw dry granulation process to provide sustained release of the 
drug.  
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CHAPTER V 
HOT-MELT EXTRUSION PROCESSING INDUCED SOLID-PHASE 
TRANSFORMATION OF LABILE ACTIVE PHARMACEUTICAL INGREDIENT: 
PREVENTIVE MEASURES 
5.1. Abstract 
Hydrates of active pharmaceutical ingredients may undergo dehydration during the 
manufacturing process and/or storage. This can affect the physiochemical properties of the 
formulation including solubility, dissolution rate, bioavailability and stability. Ondansetron 
(OND), a serotonin 5-HT3 receptor antagonist is a first choice of drug used to treat and prevent 
chemotherapy/radiotherapy/cancer surgery induced nausea and vomiting, exists in a dihydrate 
form. The main objective of this study was to understand the dehydration behavior of OND 
during hot-melt extrusion (HME) process. Differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA), dynamic vapor sorption (DVS) and hot stage microscopy 
(HSM) were used to investigate the solid state phase transformation of OND formulation due to 
HME process. 
5.2. Introduction 
     A large number of active pharmaceutical ingredients (API) are crystalline in nature and the 
crystalline solids can exist in different sub-phases such as polymorphs, hydrates, solvates and co-
crystals [76]. Understanding the nature of drug molecule crystalline sub-phases, helps in 
determining the relative physical stability in the solid state, its solution properties and its 
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absorption [77]. For example the stability and behavior of hydrates can vary widely and this may 
affect the solid state of API during the processing or storage, by phase transformation such as 
hydration, dehydration or re-hydration state. Therefore, the knowledge of crystalline sub-phases 
of API and other pharmaceutical excipients is considered to be an extremely important factor in 
the preformulation stage, in order to develop a stable pharmaceutical formulation. 
    Polymorphism in the material science is the ability of a compound or element to exist in more 
than one crystalline form. The manufacturing process can induce solid state phase transformation 
which occurs due to changes in process and formulation parameters such as humidity, 
temperature, solvent and pressure. Therefore, polymorphism of the API is the major problem in 
the pharmaceutical industry as this can affect the physicochemical properties of API and thus can 
lead to poor drug absorption, decrease the rate of dissolution and the stability of the formulation 
[78, 79].   
   Ondansetron (OND) (Fig 1) is a potent, highly selective, competitive 5-hydroxytryptamine (5-
HT3) receptor antagonist, commonly used to prevent nausea and vomiting caused by 
chemotherapy, radiotherapy and postoperative treatment. OND has been also listed in “WHO 
Model List of Essential Medicines” for basic health system [80]. Lacer et al., (1999) reported 
ondansetron polymorphs, under different experimental conditions such as pH, temperature, 
pulverization and solvents. The factors which influenced the formation of polymorphs were 
heating the sample of ondansetron over a range of temperature (40 oC to 170 oC) at various time 
intervals (5 min to 24 h), and the use of different solvents such ethanol and methanol [78]. 
Hot-melt extrusion (HME) is a well-established technology in non-pharmaceutical industries 
such as plastic, food, metal and medical devices (sutures). In last 3 decades the application of 
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HME in pharmaceutical industry has gained lot of attention due to its advantages over a 
conventional manufacturing process such as has a potential to convert a batch process into a 
continuous process, less number of processing steps, solvent-free process, easy to scale-up 
process, etc. Therefore, HME has emerged as an alternative platform technology to other 
conventional process for manufacturing wide range of pharmaceutical dosage forms such as 
granules, pellets, mini-tablets, tablets, films, implants etc [4]. HME being a thermal process, 
despite of the above mentioned advantages, it has few limitations. The main disadvantage is that 
this process cannot be utilized for heat-labile compounds as this can contribute to stability issue 
of the API. Therefore, it is essential to study the effect of different HME process parameters 
(barrel temperature, screw speed, screw configuration and feed rate) on labile active compounds. 
Till now in the literature, it has only mentioned that HME process cannot be used for sensitive, 
labile compounds, but no study has been reported to show how HME process parameters induce 
the phase transformation in active molecules. Along with this it is also important to study how 
we can optimize the HME processing parameters to prevent such a phase transformation and 
maintain the stability of the active molecule. In this study, the authors have made an attempt to 
clarify the effect of HME processing parameters on the dehydration behavior of a labile active 
pharmaceutical compound OND in the solid state. Therefore, studying the dehydration behavior 
of an active compound is crucial to predict the physicochemical properties during storage and in 
order to prevent physicochemical instability of the active compound in the formulation during 
storage optimizing the HME processing parameters is essential.   
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Fig 5.1: Ondansetron Hydrochloride Dihydrate 
5.3. Material and Methods 
5.3.1. Material 
Ondansetron HCl Dihydrate was purchased from Chemscene LLC (New Jersey, USA). 
Hydroxypropyl cellulose (KlucelTM EF) was generously gifted by Ashland Specialty Ingredients. 
(Wilmington,DE). Ethyl cellulose (Ethocel Standard 10) was kindly gifted by Dow chemical 
company. All other reagents used in this study were of the analytical grade.  
5.3.2. Methods 
5.3.2.1. Design of experiment to prepare drug-polymer extrudates via hot-melt extrusion 
process: 
Physical mixture of drug-polymer containing 20% drug, polymer ethlycellulose (EC) and 
hydroxylpropyl cellulose (HPC) in a ratio of 1:1 and  magnesium stearate (0.5%, as a lubricant) 
was prepared by using a V-shell blender (GlobePharma, MaxiblendTM New Brunswick, NJ) for 
 107 
 
20 min at 25 rpm, after passing through US# 35 mesh screen to remove any aggregates that may 
have formed. The prepared physical mixture was fed into the co-rotating twin-screw extruder (11 
mm Process 11TM, Thermo-Fisher Scientific Karlsruhe, Germany) using a volumetric feeder.  
 
Fig 5.2: Different Screw configurations 
To study the effect of screw configuration, screw speed and barrel temperature on dehydration of 
OND, the authors have designed the experiments as shown in Table 5.1 and 5.2. Briefly, three 
screw configurations (SC) were used to see the effect of shear stress on the phase transformation 
of OND that is SC with zero mixing zone, i.e. all conveying elements, second SC contain one 
mixing zone along with conveying elements and the third SC containing two mixing zones along 
with the conveying elements (Fig 5.2). Three barrel temperatures (low, medium and high) were 
utilized to prepare the drug-polymer extrudates at two screw speeds, 25 and 100 rpm. The 
prepared extrudates with the above mentioned process parameters were then characterized to 
observe the solid-state phase transformation of OND. 
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Table 5.1: Extruder process parameters (Barrel Temperature, Screw speed and Feed rate) 
 
 
  
 
 
 
 
                                  
Table 5.2: Design of experiments 
                                 
 
 
 
 
 
 
 
 
Setting 
No. 
Extruder Parameters 
1 
Feed 
Zone 
Zone 
2 
Zone 
3 
Zone 
4 
Zone 
5 
Zone 
6 
Zone 
7 
Zone 
8 
Di
e 
Screw 
Speed 
Feed 
Rate 
°C rpm g/hr 
N/A 140 140 140 140 50 50 50 40 25 or 
100 
80 
2 
Feed 
Zone 
Zone 
2 
Zone 
3 
Zone 
4 
Zone 
5 
Zone 
6 
Zone 
7 
Zone 
8 
Di
e 
Screw 
Speed 
Feed 
Rate 
°C rpm g/hr 
N/A 110 110 110 110 50 50 50 40 25 or 
100 
80 
3 
Feed 
Zone 
Zone 
2 
Zone 
3 
Zone 
4 
Zone 
5 
Zone 
6 
Zone 
7 
Zone 
8 
Di
e 
Screw 
Speed 
Feed 
Rate 
°C rpm g/hr 
N/A 90 90 90 90 50 50 50 40 25 or 
100 
80 
Batch 
# 
Screw 
Configuration 
(# of Mixing zones) 
Barrel Temp 
(℃) 
Screw speed 
(rpm) 
A1 2 90 100 
A2 2 90 25 
A3 2 110 100 
A4 2 110 25 
A5 2 140 100 
A6 2 140 25 
A7 0 90 25 
A8 0 90 100 
A9 0 110 25 
A10 0 110 100 
A11 0 140 25 
A12 0 140 100 
A13 1 90 25 
A14 1 90 100 
A15 1 110 25 
A16 1 110 100 
A17 1 140 25 
A18 1 140 100 
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5.3.3. Characterization of HME extrudates: 
5.3.3.1. Differential Scanning Calorimetry (DSC) 
Diamond DSC (Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) was used to 
study the phase transformation of OND in HME extrudates. 3-5 mg of pure API, physical 
mixture and HME extrudates were weighed and hermetically sealed in aluminum pans and the 
thermal analysis was performed over a temperature range of 25-250 °C at a heating rate of 10 
°C/min, under an inert nitrogen atmosphere at a flow rate of 20 mL/min. Endothermic onset and 
peak temperature of melting were calculated from the obtained thermogram using Pyris™ 
Manager software (PerkinElmer Life and Analytical Sciences, 719 Bridgeport Ave., CT, USA).  
5.3.3.2. Thermogravimetric Analysis (TGA) 
TGA (Pyris 1 TGA Perkin Elmer) was utilized to determine the weight loss of the pure OND.  
Weighed sample of OND was heated from 25 oC to 300 oC at a rate of 20 oC/min. in a platinum 
pan under an inert nitrogen atmosphere purge of 20 ml per minute 
5.3.3.3. Dynamic Vapor Sorption (DVS) 
The DVS (Surface Measurement Systems, London, UK) is a commercially available water 
sorption balance, which allows a sample to be weighed during exposure to defined temperature 
and humidity conditions and was employed to measure the mass change of OND during the 
isotherm dehydration studies. Approximately, 14 mg of the OND was weighed onto the 
aluminum pan. To study the phase transformation of OND under the influence of humidity, the 
DVS apparatus was programmed to run from 0% to 90% RH with the increment of 10% RH and 
then again going from 90% to 0% RH with the 10% RH increment. This allowed investigations 
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into the effects on OND after the exposure 0-90-0% RH. All experiments were run at 25 oC and 
in triplicates. The accuracy of the system is ±1.0% for the RH and ±0.2 oC for the temperature. 
5.3.3.4. Hot Stage Microscopy (HSM) 
Thermal events of OND HCl 2H2O samples were evaluated using hot-stage microscopy (HSM). 
A glass slide with a small amount of the sample was inserted into a hot-stage system (FTIR 600, 
Linkam Scientific Instruments, Surrey, UK). The sample was examined by dispersing it in 
silicone oil heated from 35 °C to 150 °C temperature range at a constant rate of 2 °C/min. A 
camera-mounted optical microscope (Cary 620 IR, Agilent Technologies, Santa Clara, CA, 
USA) equipped with a hot-stage was used to capture images at different stages of the 
transformation. 
5.4. Result and discussion 
5.4.1. DSC 
a. Effect of Screw Configuration on the easily-dehydrated drug Ondansetron: 
Effect of different screw configuration on OND phase transformation was studied by DSC (Fig 
5.3). When drug-polymer physical mixture was processed under screw configuration with all 
conveying elements, the DSC curves exhibited the melting peak of OND HCl 2H2O at 189 
oC 
which is same as physical mixture corresponding to the melting peak of dihydrate form. For one 
mixing zone screw configuration, the melting peak shifted from 189 oC (black arrow) to 179 oC 
(pink arrow) and there is occurrence of new endothermic peak at high temperature was seen at 
214 oC. The same results were obtained when two mixing zone screw configuration was used. 
The melting endothermic peak corresponding to dihydrate form shifted to lower temperature (at 
169 oC) and new dehydrated form endothermic peak was observed at 223 oC. The increase in 
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number of mixing zone results in intense mixing and high shear mechanical energy exerted on 
the material. In the HME process, there are two components responsible for melting of material 
that is energy from the heater and applied shear stress. Therefore, the design of the screw has a 
significant impact on the process and can be selected to meet particular requirements such as 
high or low shear. From the results it can be concluded that an increase in number of mixing 
zone results in further dehydration on OND HCl 2H2O. And therefore, the high shear generated 
during HME process should have an important role in OND dehydration.  
 
Fig 5.3: DSC thermogram - screw configuration effect on dehydration of OND 
b. Effect of Barrel temperature 
In order to check the effect of barrel temperature on OND dehydration, the samples extruded 
from all conveying screw configurations under low and high temperatures were scanned by DSC 
(Fig 5.4). The DSC results showed that there was no shift in the melting peak of OND between 
different processing temperatures when all conveying element screw configurations was utilized, 
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but with high temperature there was an appearance of new endothermic peak at 219 oC 
corresponding to dehydration peak of OND. However, with two mixing zone screw 
configuration at high temperature, there was only one endothermic peak observed at 217 oC 
confirming that the OND undergone complete phase transformation due to high shear as well as 
high temperature. It looks like increasing process temperatures did not generate much interaction 
between the drug and polymers. The high shear should be the main issue for drug-polymer 
interaction. For the drug dehydration, barrel temperature along with shear stress also played a 
key function generating more dehydration.  
 
 
Fig 5.4: DSC thermogram - temperature effect on dehydration of OND 
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c. Effect of screw speed  
DSC thermogram of the extrudates prepared with high and low screw speed with one mixing 
zone SC both at high and low temperature is shown in Figure 5.5 and 5.6. From the thermogram 
it was observed that screw speed do not affect the dehydration process of OND as such when 
compared to the other factors SC and barrel temperature. For both screw speeds the melting 
endothermic peak for Ondansetron was observed at 190 oC indicating no change in the DSC 
thermogram due to the change in the screw speed process parameter. 
 
Fig 5.5: One mixing zone SC at low temperature – effect of screw speed on dehydration of 
OND 
 114 
 
 
Fig 5.6: One mixing zone SC at high temperature – effect of screw speed on dehydration of 
OND 
 
5.4.2. TGA 
TGA thermogram of OND is presented in Fig 5.7. It is clearly illustrated from TGA results that 
heating of OND results in the loss of 2 moles of loosely bound water. As shown in Figure 6, ∼10 
% of weight was lost when OND heated from 60-105 oC. This value is in agreement with the 
theoretical value for 2 moles of water in OND. 
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                                 Fig 5.7: Thermogravimetric analysis of OND 
5.4.3. DVS  
Drying curve and DVS mass plot of OND is shown in Fig 5.8 and 5.9. The DVS data showed a 
significant change in mass at 0% RH for the period of 100 min. The weight loss of 9.5% at 0% 
RH is corresponding to the loss of two water molecules resulting in the dehydration of OND.  As 
the RH increased from 0% to 10% and then to 20%, there was a 2.67% and 8.9% weight gain 
was observed respectively in the DVS graph. There was a very slight gain in the weight (from 
8.9% to 9.2%) observed with the increase in RH beyond 20% upto 90%. In the DVS study, 
decreased RH only caused a slight decrease in the sample mass over 90% to 20% RH range. At 
10% RH, dihydrate starts to lose its crystal water and its weight largely decreases upto 4.44% 
corresponding to one water molecule. When humidity was further reduced, DVS data showed a 
rapid decrease in water content, indicating loss of a second water molecule from the API at 0% 
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Fig 5.8: DVS mass plot 
  
 
 
 
 
 
 
Fig 5.9: DVS Drying curve of Ondansetron HCl 2H2O 
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5.4.4. HSM 
The transition of pharmaceutical polymorphs can be visually and semi-quantitatively detected by 
hot-stage microscopy. HSM thermal events are presented in Fig 5.10. HSM results revealed that 
the dehydration event as a gradual appearance and disappearance of water bubbles starting from 
90 oC till 104 oC. Temperatures below 90 oC there was no water bubbles seen in HSM images. 
Around 156 oC, the HSM images got foggy due to the condensation of water evaporated from the 
sample on the glass surface. After cleaning the condensation on the top glass, the image was 
much clearer at temperature 179 oC. Around temperature 192 oC, drug particles started to melt 
and at 196 oC it almost completely melted. The present HSM images indicated that OND crystals 
were first dehydrated and then started to melt at temperature 192 oC. These HSM results are well 
correlates with the TGA thermogram where dehydration event was seen between the temperature 
ranges of 60-105 oC. 
 
                                       Fig 5.10: Hot stage microscopy images 
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5.5 Conclusion: 
Verification and screening stability in solid state methods proposed in this paper provide full and 
detailed information about the dehydration behavior of Ondansetron hydrochloride dihydrate. 
The thermal-dependent dehydration process of ondansetron hydrochloride dihydrate in the solid 
state was effectively studied using thermal techniques DSC and TGA. Also, hot stage 
microscopy and dynamic vapor sorption techniques were successfully used to confirm 
dehydration process of OND. In the solid state, phase transformation due to dehydration process 
induced by processing parameters may lead to the production of metastable or intermediate form 
of API. Hot melt extrusion is a thermal and shear generating process. Therefore, it is essential to 
do preliminary study to see the effect of temperature and shear on the solid state phase 
transformation of API in-order to formulate a stable product via hot melt extrusion process. From 
the results, it confirms that both shear as well as temperature is significant factor responsible for 
the dehydration of OND. It was found that screw speed do not affect dehydration process of 
OND. In conclusion, to produce stable optimized formulation of OND via HME, low shear and 
low temperature should be the choice of process parameter. 
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